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Abstract  
Vaccinia virus (VacV) is a large dsDNA virus belonging to the Poxviridae family. Due to its 
size, the VacV replication cycle occurs entirely within the cytoplasm of infected cells. This 
exposes the virus to the many intracellular DNA sensors found in human cells. Since its 
discovery in 2013, cyclic GMP-AMP Synthase (cGAS) has been shown to be the 
predominant cytoplasmic DNA sensor in many cell types, including keratinocytes. Once 
activated, cGAS generates the second messenger cGAMP to trigger IFNβ production, 
through the adaptor protein STING. VacV can limit IFN production by inhibiting this pathway 
at multiple points, but little is known about whether VacV is able to inhibit DNA sensing 
directly. To investigate this, intracellular DNA sensing within keratinocytes was analysed 
during VacV infection. Results showed that within 4 hours of infection VacV was able to 
induce the loss of cGAS to undetectable levels, effectively blocking the cell IFNβ response. 
Additional DNA sensors that cooperate with cGAS such as IFI16 remained unaffected, 
showing that cGAS is essential for the IFN response to VacV. Inhibition of host degradation 
pathways did not prevent cGAS loss during VacV infection, suggesting cGAS is directly 
targeted for enzymatic cleavage. This demonstrates a potential new mechanism VacV 
employs to limit DNA sensing through cGAS, although the viral proteins responsible remain 
elusive. Identification of these proteins may provide new treatments for certain autoimmune 
disease where overactivation of cGAS contributes to disease phenotype.  
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1 Literature Review 
1.1 Vaccinia Virus 
1.1.1 History 
Variola virus, the causative agent of smallpox, was once a devastating disease which 
resulted in epidemics in Europe up until the 19th century in addition to major outbreaks in 
Asia and Africa during the 20th century (WHO, 1979). At its highest incidence smallpox was 
prevalent worldwide and had an associated mortality rate of 30%, with survivors left 
permanently disfigured by the characteristic skin lesions (WHO, 1979). The origin of 
smallpox remains a mystery, but is believed to have emerged around 10,000 BC in northern 
Africa (Barquet and Domingo, 1997). Prior to the discovery of viruses and the immune 
system, it was common knowledge that smallpox survivors gained a lifelong immunity to the 
disease, which lead to the practice of disease survivors treating those affected (Gross and 
Sepkowitz, 1998). Consequently the first attempts at inducing smallpox immunity involved 
inoculating individuals with pustule debris from infected individuals, termed Variolation 
(Barquet and Domingo, 1997). Although often effective, the inherent risk of developing 
disseminated smallpox was still a concern, thus a new revolutionary treatment was needed; 
a treatment made possible by the work of Edward Jenner. For many years Jenner had heard 
stories of dairymaids who contracted minor infections with cowpox and subsequently gained 
a lifelong protection from smallpox (Barquet and Domingo, 1997). This lead to his conclusion 
that cowpox infections gave protection from smallpox, thus inspiring him to utilise this as a 
deliberate mechanism of protection (Gross and Sepkowitz, 1998). In 1796, Jenner took 
pustule material from a dairymaid with fresh cowpox lesions and used them to inoculate a 
young boy, who subsequently developed cowpox (Riedel, 2005). After recovery, Jenner then 
inoculated the boy with material from a fresh smallpox lesion but no disease developed. 
Jenner concluded that cowpox inoculation gave protection from smallpox. By using the Latin 
word for cow, vacca, and the term for cowpox, vaccinia; Jenner decided to call this process 
vaccination (Riedel, 2005). Due to the early work of Edward Jenner and a global 
immunisation effort lead by the World Health Organization smallpox was declared eradicated 
in 1980 (WHO, 2018). The key component was Vaccinia Virus (VacV).  
 
VacV has a long and shrouded history mainly due to its unknown origins. Analysis of VacV 
DNA has further complicated this, as it has been shown to be both closely related, and yet 
distinctly different from other members of the Orthopoxvirus genus including Variola and 
cowpox (Esposito and Knight, 1985). Further investigation into VacV based vaccines has 
shown that they are comprised of a mixture of multiple, closely related viral strains, termed a 
quasispecies, as well as bacteria and bacterial debris contaminants (Fenner et al., 1988). 
This knowledge, paired with the fact that the VacV genome shows striking instability and 
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high rates of recombination between different virus strains (Coulson and Upton, 2011), 
makes identification of VacV origin an almost impossible task. Despite its unknown history, 
VacV has been effectively used in  smallpox eradication since the introduction of the live-
virus vaccine Dryvax (Poland et al., 2005). Although effective, VacV based vaccines were 
phased out due to serious side effects, especially when a history of eczema was present 
(Fulginiti et al., 2003). This vaccine was eventually replaced by the safer, Modified Vaccinia 
Ankara (MVA) based vaccines which, due to the restrictive replication of MVA, could be 
given to immunocompromised patients (Stittelaar et al., 2001). The combination of the 
efficacy of the VacV based vaccines and the apparent lack of an animal reservoir for Variola 
resulted in the eradication of smallpox in the 1980s (Fenner et al., 1988).  
 
Although smallpox has been eradicated for almost 40 years, research into VacV and MVA is 
still of great importance, with the requirement for safe VacV and smallpox vaccines being 
driven by concerns of re-emergence. Serological based evidence show that VacV outbreaks 
involving bovines, horses and rodents have been reported in South America, with evidence 
of zoonosis to humans (Borges et al., 2018). Although discovery of a previously unknown 
natural reservoir is doubtful, re-emergence of smallpox via bioterrorism is an unlikely but 
valid concern (CDC, 2016). The most promising research avenue for VacV is its use in 
recombinant vaccines. By utilising recombinant DNA technology and exploiting the genomic 
features of VacV, recombinant vaccines could provide promising results against diseases 
such as HIV and Influenza (Sánchez-Sampedro et al., 2015).  
 
1.1.2 Structure and Genome 
Poxviridae is a large family of viruses comprised of two subfamilies Entomopoxvirinae 
(insect hosts) and Chordopoxvirinae (vertebrate hosts), with 41 species that have vertebrate 
hosts. However the genus of greatest interest is Orthopoxvirus, which contains both VacV 
and Variola virus (ICTV, 2018). All members of the Poxviridae family share the same 
characteristics; a large linear double stranded DNA genome, a replication cycle that occurs 
entirely in the cytoplasm, and a complex virion structure. The most notorious member of the 
family is the causative agent of smallpox; Variola, and the most studied and widely used in 
laboratories is VacV.  
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VacV, like all poxviruses, has an ovoid shaped membrane with multiple internal structures 
including a biconcave walled core that is flanked by lateral bodies (Figure 1). The enveloped 
virion (EV) is around 360 x 250 nm and is encapsulated by a single lipoprotein bilayer 
(Cyrklaff et al., 2005). The genome of VacV is around 200kb which encodes more than 200 
proteins that function in viral entry, replication, virion assembly and host immune evasion 
(Johnson et al., 1993). The large size of the VacV genome allows multiple foreign genes to 
be inserted to create a recombinant virus. Although the maximum foreign gene size that can 
be inserted into the VacV genome is yet to be determined, poxvirus vectors have been 
shown to have the capacity for at least 25kb DNA inserts, without affecting their replication 
(Smith and Moss, 1983). This, paired with the high immunogenicity of poxviruses and their 
high levels of gene expression, makes them an ideal candidate for the production of 
recombinant vaccines. Due to poxvirus replication being solely in the cytoplasm there is also 
a low risk of interaction with the host’s genome. Moreover genetically engineered VacV is 
also yielding promising results for cancer therapy (Thorne et al., 2005). Recombinant VacV 
virons preferentially propagate in cancer cells resulting in lysis of tumour tissue and can be 
engineered to express anti-cancer genes (Haddad, 2017). 
 
Figure 1 : Morphology of the VacV mature and enveloped virion 
The structure of the VacV virion. Shown is the single lipoprotein bilayer only present on the 
enveloped virion (EV). The VacV virion, like all poxviruses, has the unique biconcave oval shape 
with flanking lateral bodies. The large nucleocaspid is surrounded by the core wall which is 
characterised by a lipid core membrane and a protein palisade layer. This protects the nucleic 
material in the virion (SIB, 2018). 
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Due to possible of side effects when wild type VacV is used, most recombinant vaccines use 
the attenuated strain Modified Vaccinia Ankara (MVA). MVA is distinctly unique from all 
known strains of Vaccinia and other members of the Orthopoxvirus genus. It does not occur 
naturally and displays reduced virulence in humans and other mammals (Mayr et al., 1975). 
The immunogenicity of MVA is the same as VacV, hence its interest in vaccine development. 
MVA was derived from 570 serial passages of Chorioallantois Vaccinia virus Ankara (CVA) 
in chicken embryo fibroblasts (Mayr et al., 1975).  The MVA genome is much smaller than 
VacV or CVA, around 178kb compared to 200kb (Antoine et al., 1998). This is because 
during cell passage, six major deletions occurred within the CVA genome which resulted in 
the loss of around 24,000 nucleotides and caused 51 fragmented open reading frames 
(Meisinger-Henschel et al., 2007, Meisinger-Henschel et al., 2010). These deletions 
removed many human innate immune evasion proteins, hence its low virulence phenotype.  
 
1.1.3 Replication 
VacV has been shown to infect and replicate within a wide range of cell types such as; 
keratinocytes, fibroblasts, and leukocytes (Sánchez-Puig et al., 2004, Liu et al., 2005). 
However, VacV shows preferential replication within dermal cells, specifically fibroblasts and 
keratinocytes, causing the characteristic skin lesions in the infected host (Liu et al., 2005). 
VacV has also been shown to infect T cells and dermal dendritic cells, although this results 
in an abortive infection (Liu et al., 2005). HaCaT cells were the chosen cell line used in this 
project for VacV and MVA infections. HaCaT cells are a spontaneously transformed immortal 
keratinocyte cell line, that is similar to normal human keratinocytes when grown in vitro 
(Boukamp et al., 1988). 
 
VacV has two main infectious forms, mature virion (MV) and extracellular/enveloped virion 
(EV), therefore the virus has different cell entry mechanisms dependent on the infectious 
form. The main process in which VacV facilitates host cell entry is via macropinocytosis as it 
is the most appropriate for endocytosis of large particles (Mercer et al., 2010). The process 
of endocytosis begins when virus-receptor interactions occur, resulting in intracellular 
transportation prior to membrane fusion (Liu et al., 2014). This process is also similar 
between VacV strains, however each strain uses a distinct form of macropinocytosis relying 
on different host receptors and entry mechanisms (Mercer et al., 2010). 
 
After the virus enters the cell and disassembles, infection-specific concentrated cytoplasmic 
domains form; referred to as “viral factories” (Tolonen et al., 2001). These factories form 
immediately following host cell entry, before viral replication, and consist of cellular derived 
components, specifically an endoplasmic reticulum derived membrane cisternae which 
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facilitates viral replication (Tolonen et al., 2001). DNA replication, protein translation and 
virion assembly all occur within these viral factories (Katsafanas and Moss, 2007). After viral 
replication and assembly, scaffold proteins are removed and membrane restructuring occurs 
resulting in formation of the mature virion. Many viral and host proteins have been found to 
play a role in this restructuring, but the exact process remains controversial (Liu et al., 2014). 
Mature virions are then transported out of the viral factories to be further processed into an 
enveloped virion. This is assisted by host microtubules trafficking these MV to the cell 
surface. During this translocation the virion becomes encapsulated in a double membrane 
derived from the trans-Golgi network, this results in the formation of the EV (Liu et al., 2014, 
Roberts and Smith, 2008). When at the cell surface, fusion with the plasma membrane 
occurs, where the formation of an actin tail below the membrane associated EV promotes its 
release from the cell (Horsington et al., 2013). 
 
1.2 Innate Immunity: Overview 
The Innate immune system is a non-specific host defence mechanism that responds rapidly 
to microbial exposure. The aim of this response is to limit the spread of any potential 
pathogens within the body as well as activating the more specific adaptive immune response 
(Iwasaki and Medzhitov, 2015). Microorganisms are initially recognised by the host germline-
encoded pattern recognition receptors (PRRs), by interacting with their corresponding 
pathogen-associated molecular patterns (PAMPs) (Akira et al., 2006). These PAMPs are 
usually essential components of the microorganism and are therefore rarely altered, a factor 
exploited by PRRs. There are several PRRs each tailored towards activating a specific 
branch of the immune system; of which the family of Toll-like receptors (TLRs) are one of the 
largest and most studied (Medzhitov and Janeway, 2000). This, paired with the constitutive 
expression of PRRs, is the conserved initiation point of innate immune processes. 
 
The innate immune system consists of several parts and mechanisms that interplay to limit 
microbe entry, dissemination and ability to cause disease. The key elements of the innate 
immune system include physical barriers, humoral anti-microbial products and cell-mediated 
defence mechanisms (Romo et al., 2016). A summary of key components in the innate 
immune system is represented in Figure 2. 
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1.2.1 Physical barriers 
Physical and chemical barriers have a vital role of isolating the internal environment from 
external elements, such as potentially pathogenic microorganisms as well as harmful 
substances (Elias, 2007). The main physical barrier in humans is the epidermis, specifically 
the stratum corneum (Elias, 2005). The epidermis functions as a barrier against a broad set 
of stimuli; for example, pathogenic microorganisms, foreign chemicals, oxidative stress, and 
is able to act as a cutaneous inflammation interface (Elias, 2007).  
 
1.2.2 Humoral innate immunity 
The humoral innate immune response encompasses all soluble macromolecules found in 
extracellular fluids that contribute to antimicrobial activity. This is one of the largest branches 
of the innate immune system as it consists of multiple components, including pentraxins, 
natural antibodies, and the complement system (Shishido et al., 2012).  
 
 
Figure 2: An overview of the innate immune system. 
An overview of innate immune components within humans. The function of physical and chemical 
barriers, humoral immunity, and cell mediated immunity are shown. The pathogen shown is non-
specific and may represent either bacterial, viral or fungal, depending on the mechanism shown 
(Romo et al., 2016). 
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Pentraxins 
Pentraxin are a family of evolutionary conserved, multimeric proteins characterised as a 
class of PRR. They are acute phase proteins that are synthesised rapidly during infection, 
therefore are often used as biomarkers for infection and inflammation (Du Clos and Mold, 
2004). There are two main types of pentraxins; long and short. This is denoted by the 
presence or absence of further domains, in addition to the common C terminal domain. Short 
pentraxins include C-reactive protein and serum amyloid P, whereas the primary long 
pentraxin is pentraxin 3 (Pepys and Baltz, 1983). The main role of pentraxins is to recognise 
and bind to pathogens and apoptotic cells. This interaction is then recognised by 
macrophage Fc receptors facilitating clearance of cell debris and potential pathogens (Mold 
et al., 2001). 
 
Natural Antibodies 
Produced mainly by the B1 subset of B lymphocytes, Natural antibodies (NAb) are non-
specific immunoglobulins synthesised by cells in the absence of pathogens (Baumgarth et 
al., 2005). Their function is similar to that of pathogen specific antibodies, however NAb can 
recognise a wide range of epitopes but exhibit low binding affinity. Despite this they are 
essential for clearance of cellular debris, recruitment of complement components and 
modulating the adaptive immune response (Ochsenbein et al., 1999). 
 
Complement 
The complement system is a complex cascade composed of serum proteins that interact 
with pathogens resulting in inflammation, opsonisation and lysis of microbes (Stoermer and 
Morrison, 2011). Activation can occur via three converging pathways; classical, alternate, 
and mannose binding lectin pathway (Dunkelberger and Song, 2010). Although each 
pathway differs mechanistically, they all result in the cleavage of C3 and C5 by their 
respective convertase enzymes causing C5b deposition, initiating the common terminal 
pathway (Dunkelberger and Song, 2010). The action of the complement cascade results in 
the formation of a membrane attack complex, which results in lysis of either microbes or 
infected cells. 
 
1.2.3 Cell mediated innate immunity 
Cell mediated innate immunity is a major part of the innate defence against intracellular and 
extracellular pathogens, with the main cellular components functioning as either phagocytic 
cells or cytotoxic cells (Alberts et al., 2008). The vast majority of these innate immune cells 
derive from myeloid precursor cells, with the exception of natural killer cells and B1 
lymphocytes; both of which arise from a common lymphoid progenitor (Alberts et al., 2008). 
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The main cellular components of the innate immune system are professional phagocytes; 
macrophages and granulocytes, and natural killer cells (NK cells). 
 
Phagocytes 
The main cellular components of the innate immune system are myeloid phagocytic cells, 
more commonly referred to as professional phagocytes. These type of leucocytes include 
neutrophils, monocytes, macrophages, basophils and eosinophils (Alberts et al., 2008). The 
main role of these cells is to engulf (phagocytose) and destroy pathogens, as well as secrete 
cytokines and soluble mediators, such as histamine, lysozymes, and interleukin 12 (IL-12) 
(Tripp et al., 1993). As well as destroying pathogens, the soluble mediators released, 
especially IL-12, drive NK and T lymphocytes to produce interferons (IFN), specifically IFNγ. 
Which in turn leads to further activation of macrophages, increasing their antimicrobial 
activity (Tripp et al., 1993).  
 
Natural Killer cells 
Natural killer cells are a large granular lymphocytes within the innate immune system and 
are remarkably similar to T and B lymphocytes of the adaptive immune system. Unlike T and 
B lymphocytes, NK cells do not undergo somatic hypermutation, therefore do not alter 
receptors from their germline structure (Caligiuri, 2008). Instead NK cells express a 
repertoire of receptors, both inhibitory and activating, that are tailored to ensure self-
tolerance while rapidly responding to microbial challenge. Once activated NK will initiate 
apoptosis in virally infected cells as a means to limit viral replication and spread (Vivier et al., 
2011). As well as this, NK cells have also been shown as the major producer of cytokines, 
both inflammatory (TNFα) and immunosuppressive (IL-10) (Moretta and Moretta, 2004). 
 
1.3 Innate immunity to viruses 
Due to their mechanism of action, phagocytes are more tailored to destroying extracellular 
pathogens, mainly bacteria and parasites, whereas NK cells are more tailored to intracellular 
pathogens such as viruses. Primary infected cells, such as keratinocytes during VacV 
infection, have their own intracellular innate processes to detect and limit viral infections. 
Host cells are able to recognise viral infection and mount a strong antiviral response to 
destroy and limit the spread of the pathogen. This occurs by the innate immune system 
recognising viral components through pattern recognition receptors (PRRs) (Medzhitov, 
2007). There are three main classes of PRRs responsible for recognition of viral 
components, Toll-like receptors (TLRs), nucleotide-binding oligomerisation domain-like 
receptors (NLRs),and retinoic acid-inducible gene-I-like receptors (RLRs) (Hansen et al., 
2011) . These PRRs can recognise a wide variety of viral components including DNA, single 
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stranded RNA, 5’-triphosphate capped double stranded RNA, and soluble viral proteins 
(Hansen et al., 2011). Of the aforementioned receptors, TLRs and RLRs are important for 
the production of type I interferons and other various cytokines, whereas NLRs have a more 
regulatory role. 
 
1.3.1 Toll-Like Receptors 
Toll-like receptors are a family of membrane spanning, non-catalytic receptors commonly 
expressed on sentinel immune cells such as macrophages. There are currently ten known 
TLRs in humans each activated by a specific ligand, covering a wide range of different 
molecular patters found in microorganisms (Tartey and Takeuchi, 2017). They are found in 
two primary locations within cells, either at the cell surface or compartmentalised within the 
cell inside an endosome (Botos et al., 2011). All TLR family members are structurally similar 
with the presence of a leucine-rich repeat domain within their extracellular region, a 
transmembrane domain, and a conserved Toll IL-1 receptor (TIR) domain; named due to 
their homology with IL-1 receptor signalling domains (Botos et al., 2011). Irrespective of their 
ligands, the TIR domains of TLRs converge and activate several common signalling 
pathways, resulting in either the activation of mitogen activated protein (MAP) kinase and the 
transcription factor NF-κB to stimulate cytokine production or activating interferon regulatory 
factors (IRFs) to promote type I interferon production (Beutler, 2004). For viral infections the 
most important TLRs are TLR3, TLR7 and TLR9, as these detect double stranded RNA, 
single stranded RNA, and unmethylated CpG oligodeoxynucleotides, respectively (Tartey 
and Takeuchi, 2017). However, TLRs are limited in their capacity to detect viral components, 
as they can only detect viruses within the extracellular and endosomal spaces. However 
other PRRs, NLRs and RLRs, are able to cover this potential gap.  
 
1.3.2 RIG-I-like Receptors 
Upon host cell entry, many viruses are able to avoid exposing their genomic material to 
endosomal TLRs, specifically viruses that contain a lipid envelope. Despite this, activation of 
the type I IFN response to viral infection is achieved by cytoplasmic detection of non-self 
RNA by the RLR family of receptors. There are three known RLRs; retinoic acid-inducible 
gene (RIG-I) (Yoneyama et al., 2004), melanoma differentiation-associated antigen 5 
(MDA5) (Kang et al., 2002), and laboratory of genetics and physiology 2 (LGP2) (Miyoshi et 
al., 2001). Both RIG-I and MDA5 belong to a DExD/H-box helicase family with an N-terminal 
caspase activation and recruitment domain (CARD) that senses viral RNA with its helicase 
domain. After sensing, a downstream signal is transduced by CARD, therefore these two 
proteins share homologous function (Yoneyama et al., 2005). In contrast, LGP2 lacks a 
CARD domain and was originally identified as a negative regulator of RLR signalling by 
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interfering with viral RNA recognition by RIG-I and MDA5 (Yoneyama et al., 2005). However, 
recent studies have shown LGP2 as a potential cofactor of MDA5 which can assist in MDA5-
mediated IFN signalling (Satoh et al., 2010, Hei and Zhong, 2017).  
 
Both RIG-I and MDA5 are able to directly bind viral RNA via their helicase domain, however 
they display different binding specificity. MDA5 binds to long (greater than 2kb) double 
stranded RNA species (Kato et al., 2008), whereas RIG-I binds shorter double stranded 
RNA and 5’-triposphate capped RNA (Hornung et al., 2006). Activated RLRs interact and 
activate mitochondrial antiviral-signalling protein (MAVS), also known as IPS-1, which then 
forms prion-like aggregates that convert other inactive MAVS into its functional multimeric 
state (Hou et al., 2011). This results in the activation of two distinct signalling pathways. One 
pathway involves the activation of TBK1 and IRFs, leading to IFN production, whilst the other 
pathway signals via the kinase complex IKK, resulting in the activation of NF-κB and 
upregulation of proinflammatory genes (Belgnaoui et al., 2011). 
 
1.3.3 NOD-like Receptors 
The final class of PRRs important for recognition of viral infections are the nucleotide-binding 
oligomerisation domain-like (NLR) family of receptors. The NLR family of receptors consist of 
multi-domain proteins, each with a variable N-terminal caspase recruitment domain (CARD) 
and pyrin domain (PYD), a central nucleotide-binding oligomerisation domain (NOD) 
essential for receptor activation, and a C-terminal leucine-rich repeat region responsible for 
PAMPs sensing (Harton et al., 2002). When a PAMP is sensed by the C-terminal leucine-
rich repeat region, a conformational change occurs that results in the oligomerisation of the 
NOD domain (Inohara et al., 1999, Kanneganti, 2010). This conformational change results in 
exposure of the CARD and PYD domains, which in turn recruits and activates CARD and 
PYD containing effector molecules (Inohara et al., 1999). As a result of this, NLRs activate 
many signalling pathways such as nuclear factor-κB (NF-κB), mitogen activated protein 
kinase (Kanneganti et al., 2007), and IRF dependent IFN production via mitochondria 
associated antiviral signalling protein (MAVS) (Sabbah et al., 2009). As well as activating 
downstream signalling proteins, NLR family members specifically NLRP1, NLRP3 and 
NLRC4 can form large protein complexes called inflammasomes (van de Veerdonk et al., 
2011). These NLRs form inflammasomes by activating caspases, specifically caspase 1, 
which in turn generates the active proinflammatory cytokines interleukin-1β and IL-18 
(Fantuzzi and Dinarello, 1999). High levels of IL-1β and IL-18 have been shown to lead to an 
inflammatory form of programmed cell death, pyroptosis (Martinon et al., 2002). 
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All three of these aforementioned PRRs work in tandem to detect intracellular and 
extracellular viruses and activate further innate immune signalling. A summary of each is 




Interferons are secreted glycoproteins which possess potent antiviral properties. Within 
humans, there are three classes designated Type I, II and III. Type I IFNs are the largest 
class of the three and include primarily 13 IFN-α subtypes and one IFN-β gene, as well as 
other more specialised IFNs such as IFNs δ, ε, κ, ω, and τ, and all bind to the same 
ubiquitously expressed receptor IFNAR (McNab et al., 2015). Type II IFN (IFNγ) is secreted 
by activated immune cells, primarily NK and T-cells, resulting in the activation of the cell 
mediated adaptive immune response. Finally, Type III IFNs (IFNλ) share similar function to 
type I IFNs as they activate the same intracellular signalling pathway and perform many of 
the same anti-viral activities (Kotenko et al., 2003, Sheppard et al., 2003). However, 
expression patterns of type III IFN differ from type I, as it is mainly restricted to cells of 
epithelial origin (Donnelly and Kotenko, 2010). All three classes of IFNs play an important 
role in the antiviral effects against VacV infection. 
Figure 3: The roles of TLRs, RLRs and NLRs in pathogen sensing 
Three classes of pattern recognition receptors involved in intracellular and extracellular viral sensing. 
Shown are the main downstream effectors when each receptor is activated. See text for a more 
detailed description of their structure and role in sensing viral infection (Shayakhmetov, 2010) 
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The IFN response is initiated by the recognition of PAMP by cellular PRRs, which include 
TLRs, RLRs and cytosolic DNA sensors. Each PRR has its own signalling process, but all 
result in the activation of transcription factors and their translocation to the nucleus (McNab 
et al., 2015). The transcription factors activated during the IFN response include IRFs 1 3 
and 7, activator protein 1 (AP-1) and NF-κB (Akira et al., 2006). Each IRF is able to activate 
transcription of different IFNs; IRF3 induces transcription of IFNβ genes (Sato et al., 2000), 
IRF7 induces transcription of both IFNα and IFNβ genes (Sato et al., 2000), and IRF1 
promotes IFNλ transcription (Siegel et al., 2011). While both IRF7 and IRF3 can activate 
transcription from IFNβ genes, IRF7 is the master regulator of type I IFN response, as it is 
essential for the full function of all elements of the IFN response (Honda et al., 2005). 
Furthermore, the transcription factors NF-kB and AP-1 work alongside IRFs in cytokine 
production to regulate the transcribed genes (Iwanaszko and Kimmel, 2015). 
 
When produced, IFNs are secreted from the cell and promote either autocrine or paracrine 
signalling through their respective interferon receptors. When bound to their receptors IFNs 
initiate a signal cascade through the proteins Janus kinase (JAK) and signal transducer and 
activator of transcription (STAT). Signalling activated by either type I or III IFNs result in the 
formation of the ISGF3 complex containing; STAT1, STAT2 and IRF9 (Horvath et al., 1996, 
Zhou et al., 2007). When formed ISGF3 binds to IFN-stimulated response elements (ISRE) 
and induces the transcription of these genes (Takaoka and Yanai, 2006). In contrast, 
signalling of type II IFNs occurs via the STAT1 homodimer that binds to gamma-activated 
sequences (GAS) and promotes gene transcription (Takaoka and Yanai, 2006). The process 
of IFN production and IFN action is summarised in Figure 4. 
 
There are several hundred interferon stimulated genes and the action of IRF and STAT 
signalling ensures a coordinated expression in response to viral infection. These proteins 
produced via IFN signalling possess potent antiviral properties. The protein kinase PKR is an 
important effector of IFN stimulation, effectively controlling viral replication. Active PKR is 
able to phosphorylate the eukaryotic translation initiator factor eIF-2α and inhibit translation 
as well as mediating apoptosis (Saelens et al., 2001, Srivastava et al., 1998). Another 
protein produced by IFN signalling is the protective protein ubiquitin-like protein ISG15, 
which is able to form conjugates with many proteins via ISGylation. ISGylation displays 
potent antiviral properties by conjugating with viral proteins preventing their function or by 
forming a complex with host proteins preventing their degradation (Morales and Lenschow, 
2013).  










Figure 4: The role of interferon regulatory factors and the Interferons they produce 
in antiviral gene expression 
A. Interferon regulatory factors (IRFs) are key transcriptional factors that work alongside NF-κB to 
promote IFN gene expression. This process is initiated by PRR activation and subsequent 
downstream proteins. Signalling via TLR2 results in Myd88 activation, which in turn 
phosphorylates IRF7 promoting IFNα transcription. Other TLRs are able to activate either; IRF3 
via TBK1, or IRF7 via TRAF3 leading to the transcription of IFNβ and IFNα respectively. TLRs 
are not the only activators of IRF3 and 7 as cytoplasmic nucleic acid sensors are able to 
promote TBK1 activation and subsequent IRF phosphorylation. Finally IRF1 promotes the 
transcription of the type III interferons (IFNλ), via RNA sensing and MAVS activation (Handfield 
et al., 2018). 
B. Once produced IFNs exit the cell and bind to their respective IFN receptors. Binding of either 
type I or III interferons to their receptors resulting in the phosphorylation of STAT1 and STAT2, 
which complex with IRF9 to transcribe ISRE containing genes. Whereas, binding of type II 
interferons to their receptor resulting the formation of the STAT1 homodimer GAF, which is 
able to bind GAS elements to promote gene transcription. IL-27 signalling through IRF3  is also 
shown (Handfield et al., 2018). 
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1.5 Intracellular DNA sensing 
 
The endosomal TLR9 is the only TLR that is able to sense DNA by specifically binding to 
unmethylated cytosine-guanosine containing (CpG) motifs within DNA and trigger IFN 
production, a feature commonly found in bacterial and viral genomes but rare within the 
human genome (Hemmi et al., 2000). Despite this, TLR9 independent activation of the 
innate immune system by DNA has been observed. Studies in TLR9 deficient mice still 
exhibited IFN-β production in response to DNA, suggesting a novel TLR9 independent DNA 
sensing mechanism (Okabe et al., 2005). Before any potential TLR independent DNA 
sensors were discovered it was clear that signalling via TANK-binding kinase 1 (TBK1) and 
IRF3 was pivotal to the DNA response that resulted in induction of type I IFNs (Stetson and 
Medzhitov, 2006, Ishii et al., 2008). A major breakthrough for understanding intracellular 
DNA sensing occurred with the discovery of the endoplasmic reticulum (ER) bound 
stimulator of IFN genes (STING) (Ishikawa and Barber, 2008). STING was identified as a 
crucial upstream adaptor of TBK1 and IRF3 in the DNA response pathway (Zhong et al., 
2008, Tanaka and Chen, 2012). However, how DNA activates STING signalling has been 
studied intensely and yielded a surprising number of upstream sensors (see Figure 7 for a 
summary of these pathways).  
 
1.5.1 The cGAS-STING pathway 
Hailed as one of the most important discoveries with regards to DNA sensing, cyclic GMP-
AMP synthase (cGAS) has been shown to be a central regulator of cytosolic DNA sensing. 
Discovered in 2013, cGAS is unique amongst DNA sensor as, when DNA bound, it is able to 
produce a potent second messenger to activate type I IFN production (Sun et al., 2013). A 
summary of this process is shown in Figure 5. 
 
An activation loop within the cGAS molecule is able to bind DNA in a sequence independent 
manner by interacting with the sugar-phosphate backbone, but not to any of the bases (Civril 
et al., 2013). cGAS can also bind to single stranded DNA (ssDNA), under specific 
circumstances. Y-Shaped ssDNA that forms a duplex structure and contains unpaired 
guanosine overhangs are highly stimulatory and activate cGAS (Herzner et al., 2015). 
Although rare, these structures have been found to occur during early human 
immunodeficiency virus 1 (HIV-1) infection of macrophages (Herzner et al., 2015). 
Surprisingly, A-form dsRNA is also able to bind to cGAS but is unable to activate it, due to its 
inability to induce the necessary conformational change that results in cGAS activation 
(Zhang et al., 2014). 
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Once DNA is bound a dramatic conformational change occurs exposing Lys384, a positively 
charged region, allowing further DNA binding (Zhang et al., 2014). This DNA binding results 
in the activation loop moving inwards causing rearrangement of the catalytic site, resulting in 
cGAS activation. Once activated, cGAS catalyses a 2’-5’ and 3’-5’ phosphodiester linkage of 
cyclic guanosine monophosphate (GMP) and cyclic adenosine monophosphate (AMP), 
producing the second messenger cyclic GMP-AMP (cGAMP) (Diner et al., 2013, Sun et al., 
2013). This is a twostep process starting first with the synthesis of linear 2’-5’ linked 
dinucleotides, which then undergoes cGAS-depended cyclisation through 3’-5’ linkage 
(Ablasser et al., 2013a). This process is also observed in multiple cell types after DNA 
transfection or viral infection, leading to detectable levels of cGAMP (Diner et al., 2013).   
 
Once produced, cGAMP is then able to bind to the endoplasmic reticulum (ER) associated 
adaptor stimulator of interferon genes (STING) with higher affinity than bacterial cyclic 
dinucleotides (Wu et al., 2013, Ishikawa and Barber, 2008). In its non-active state, STING 
exists as an ER anchored dimer with a cyclic diguanylate monophosphote binding domain 
(CBD) facing the cytosol (Yin et al., 2012). As well as this, the CBD and the C-terminal tail of 
STING interact causing autoinhibition (Yin et al., 2012). cGAMP is able to bind directly to 
STING, within the groove created by the association of its two monomers, causing 
displacement of the C-terminal tail and recruitment of the ER protein autocrine motility factor 
receptor (AMFR). This process occurs in an insulin-induced gene 1 (INSIG1) dependent 
manner (Wang et al., 2014). This AMFR-INSIG1 complex displays E3 ubiquitin ligase 
activity, which results in the polyubiquitination of STING. This modification allows the 
anchoring of the serine/threonine kinase TBK1 and results in STING dimerisation and 
translocation to the perinuclear region, via the Golgi (Ishikawa et al., 2009). While 
translocating via the Golgi, STING undergoes palmitoylation on Cys88 and Cys91, an event 
essential for activation of TBK1 (Mukai et al., 2016). TBK1 is then able to phosphorylate 
STING on Ser366, allowing STING to stimulate IRF3 phosphorylation by TBK1 (Hemmi et 
al., 2004, Tanaka and Chen, 2012). Phosphorylated IRF3 then forms a homodimer and 
translocates to the nucleus where it promotes the transcription of IFNβ genes (Au et al., 
1995, Sato et al., 2000). STING-TBK1 also activate IκB kinase (IKK), which then 
phosphorylates the IκB family of inhibitors associated with the transcription factor NF-κB 
(Abe and Barber, 2014, Ishikawa and Barber, 2008). Phosphorylation of IκB proteins leads 
to their proteasomal degradation; releasing NF-κB, which enters the nucleus and cooperates 
with IRF3 to induce IFN production, as well as other inflammatory cytokines such as tumour 
necrosis factor alpha (TNFα) (Abe and Barber, 2014). A unique aspect of the cGAS-STING 
response is that cGAMP is able to be transferred between infected and nearby cells via gap 
junctions (Ablasser et al., 2013b). Furthermore, cGAMP can be incorporated during virion 
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assembly and transferred to newly infected cells (Bridgeman et al., 2015). This cell to cell 
transmission of cGAMP propagates an IFN response in neighbouring and newly infected 
cells, limiting the dissemination of viruses.  
Figure 5: The cGAS-STING pathway during cytosolic DNA sensing 
DNA within the cytoplasm is a major PAMP that activates the innate immune response. Cytoplasmic 
DNA can originate from multiple sources such as DNA viruses, retroviruses, bacteria, and damaged 
self-DNA. Regardless of source, cytoplasmic DNA binds and activates cGAS, which catalyses the 
production of the second messenger cGAMP from ATP and GTP, which then binds to the ER adaptor 
STING. As well as cGAMP, cyclic dinucleotides produced by some bacteria can also directly bind 
STING causing its activation.  Once bound to its ligand, STING is then trafficked to the ER-Golgi 
intermediate compartment (ERGIC) and finally to the Golgi. STING then activates TBK1, which 
phosphorylates STING causing recruitment of IRF3 to the complex. Once associated with STING, 
IRF3 is phosphorylated by TBK1 resulting in its dimerisation and translocation to the nucleus. STING is 
also able to activate the kinase IκB which phosphorylates the NF-κB inhibitor IκBα, resulting in its 
proteasomal degradation. Once dissociated from IκBα, NF-κB translocates to the nucleus. Both IRF3 
and NF-κB cooperate to induce the expression of genes encoding IFN-β (Chen et al., 2016). 
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1.5.2 Regulation of the cGAS-STING pathway 
Stimulation of IFN production by DNA sensing via the cGAS-STING pathway is a potent 
antiviral mechanism. However, constant or aberrant activation of this pathway can lead to 
elevated type I IFN expression, which is linked to several autoimmune diseases; 
interferonopathies (Crow, 2015). Therefore, the cGAS-STING pathway is under tight 
regulation to ensure appropriate activation.  
 
The pathway is initiated when cGAS binds to dsDNA. However many mechanisms regulate 
this to ensure an appropriate response to foreign DNA while remaining unresponsive to self-
DNA. One of the main methods of regulation is post translational modification. The kinase 
Protein kinase B (PKB), also known as Akt, is able to phosphorylate human cGAS at Ser305 
and inhibit its enzymatic activity (Seo et al., 2015). This suggests that pathways involved in 
the regulation of PKB also are able to regulate cGAS activity. cGAS can also be modified by 
the addition of monoglutamic or polyglutamic residues, known as glutamylation, by the 
tubulin tyrosine ligase-like (TTLL) proteins TTLL4 and TTLL6 (Janke et al., 2005, Xia et al., 
2016a). Polyglutamylation by TTLL6 prevents DNA binding to cGAS, whereas TTLL4 
monogultamylation blocks its enzymatic activity (Xia et al., 2016a). This modification can be 
reversed by the carboxylpeptidases CCP6 and CCP5; which can remove poly and 
monoglutamylation respectively, leading to cGAS activation (Xia et al., 2016a). By tightly 
regulating the inhibitory phosphorylation or glutamylation of cGAS, pathway initiation can 
occur to eradicate DNA viral infections or be supressed to prevent an excessive immune 
response. After STING activation, and subsequent IFN production, the activated protein is 
translocated from the ER and packaged in vesicles. STING is then phosphorylated by UNC-
51-like kinase (ULK1), promoting STING degradation by autophagy and repressing IRF3 
function (Konno et al., 2013). This process is triggered by the cyclic dinucleotide cGAMP. 
This suggest that cGAMP initiates STING signalling initially, but triggers negative feedback 
control after activation, preventing persistent transcription of IFN genes by IRF3. (Gonugunta 
et al., 2017, Konno et al., 2013) 
 
Another mechanism for the control of the cGAS-STING pathway is by transcriptional and 
epigenetic regulation. Many cancer cells have lost the expression of both cGAS and STING, 
allowing evasion of the host immune system (Xia et al., 2016b). In many cancer cell types, it 
was found that both STING and cGAS were silenced by the epigenetic process 
hypermethylation, a process which can be reversed by demethylation (Xia et al., 2016b). In 
addition to cancer cells, both T-cells and hepatocytes also lack a functional cGAS-STING 
pathway, and therefore may contribute to infection with HIV and hepatitis B, respectively 
(Berg et al., 2014, Thomsen et al., 2016). This suggest a role for cGAS-STING pathway 
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silencing by methylation within primary cells. Finally, the intracellular secondary messenger 
cGAMP is regulated by its rate of synthesis and decay. The extracellular enzyme 
ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) is able to degrade cGAMP 
with high specificity within murine and porcine cells (Li et al., 2014, Wang et al., 2018b). 
However, the role of ENPP1 in cGAMP regulation in humans is yet to be determined.   
 
1.5.3 Additional DNA Sensors 
cGAS is not the only DNA sensor able to stimulate IFN production through STING activation. 
Many DNA sensors exist that are able to perform the same role as cGAS, however many are 
only found in specific cell types and their importance in DNA sensing is poorly understood. 
While the pathway from STING activation to IRF production is mostly the same, many DNA 
sensors have distinct mechanisms that lead to the activation of STING. As well as this, there 
are some distinct DNA sensors that are able to stimulate IFN production, without STING 
activation.   
 
DNA- dependent activator of IRFs (DAI) 
DAI, known also as Z-DNA binding protein 1, was the first DNA sensing receptor found to 
function directly upstream of STING (Takaoka et al., 2007). It contains a Z-binding domain, 
critical to its function, which is able to bind nucleic acids that adopt the atypical Z 
conformation (Maelfait et al., 2017). It was shown to bind DNA and RNA from a multitude of 
sources including viral, bacterial and mammalian DNA. Furthermore, artificially induced 
dimerisation of DAI also resulted in activation of IFN I genes  (Wang et al., 2008). Alongside 
IFN gene activation, sensing of viral nucleic acids by DAI can also trigger the DAI-RIPK3 
dependent necroptosis pathway (Nogusa et al., 2016). This has also been observed in VacV 
infected cells (Chan et al., 2003). Although DAI displays properties of a nucleic acid sensor, 
its role in the innate immune system is unclear as it displays redundancy in DNA sensing 
within certain cell types (Lippmann et al., 2008) 
 
PYHIN Family  
The PYHIN family of DNA sensors are characterised by the presence of the Pyrin and 
HIN2000 domains, and many of the family are inducible by IFNs (Schattgen and Fitzgerald, 
2011). Absent in melanoma (AIM2) was identified as the first PYHIN family to act as a PRR 
for intracellular DNA, and therefore defines a sub-family of AIM2-like receptors (DeYoung et 
al., 1997, Schattgen and Fitzgerald, 2011). AIM2 is an intracellular dsDNA sensor which 
activates caspase 1 leading to IL-1β production (Fernandes-Alnemri et al., 2009). Another 
AIM-2 like receptor shown to act as a PRR for intracellular DNA was γ-Interferon Inducible 
protein (IFI16) (Unterholzner et al., 2010). IFI16 is able to directly bind double stranded DNA 
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in a non-sequence specific manner, mediated by the two HIN domains of the protein (Jin et 
al., 2012). Upon activation, IFI16 associates with STING and promotes the activation of both 
IRF3 and NF-κB (Unterholzner et al., 2010). Furthermore, IFI16 has also been shown to 
activate the inflammasome after viral infection (Ansari et al., 2013). Unlike other DNA 
sensors IFI16 has been shown to be vital for the IFN response to DNA in many cell types, 
such as human fibroblasts, monocytes and dendritic cells (Unterholzner et al., 2010, Duan et 
al., 2011). Its function is also unique amongst DNA sensors as it is able to shuttle between 
the cytoplasm and the nucleus, as well as sensing DNA in both regions (Dell'Oste et al., 
2014, Kerur et al., 2011, Orzalli et al., 2012). IFI16 has also been shown to cooperatively 
work with other DNA sensors to induce IFN production. In human keratinocytes, cGAS and 
IFI16 cooperate during DNA sensing to fully activate the innate immune response and 
prevent spurious IFN activation (Almine et al., 2017). However, AIM2-like receptors have 
been shown to be dispensable in murine models and during human cytomegalovirus 
infection (Gray et al., 2016), casting doubt over the extent IFI16 contributes to viral DNA 
sensing. 
 
DEAD-Box Helicase 41 (DDX41) 
DDX41, a member of the DEAD-box helicase protein family, was first identified as an 
intracellular DNA sensor within myeloid dendritic cells. Knockdown of DDX41 blocked the 
activation of TBK1, NF-κB and IRF3 within dendritic cells when exposed to viral DNA (Zhang 
et al., 2011b). Like most DNA sensors DDX41 uses STING as an important adaptor protein 
to facilitate signal transduction from the activated sensor to downstream TBK1 and IRF3, 
resulting in production of type I IFNs (Zhang et al., 2011b). DDX41 is able to directly bind 
both DNA and STING via its conserved Asp-Glu-Ala-Asp (DEAD) domain (Linder et al., 
1989, Zhang et al., 2011b) 
 
Alongside viral DNA, DDX41 is also able to bind bacterial cyclic dinucleotides di-GMP and 
cyclic di-AMP and trigger type I interferon response in the host (Parvatiyar et al., 2012). 
These cyclic dinucleotides are released by certain bacterial species and used as secondary 
messengers, as well as triggering STING depended signalling in mammalian cells (Hengge, 
2009, McWhirter et al., 2009). As with viral DNA sensing, the DEAD domain of DDX41 is 
essential in detecting cyclic dinucleotides thus triggering a type I interferon response 
(Parvatiyar et al., 2012). After binding these dinucleotides, DDX41 then promotes the binding 
of STING to form a dinucleotide-DDX41-STING complex, resulting in STING activation 
(Parvatiyar et al., 2012). Other dinucleotides have also been shown to directly bind STING, 
notably cyclic cGAMP, (Wu et al., 2013) although the ability of DDX41 to bind cGAMP is still 
undetermined.  
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DNA dependent protein kinase (DNA-PK) 
DNA-PK is a heterotrimeric complex of proteins, consisting of three proteins Ku70, Ku80 and 
a DNA-dependent protein kinase catalytic subunit (DNA-PKcs) (Ferguson et al., 2012). Both 
the Ku70 and Ku 80 subunits form a basket shaped heterodimer and works alongside DNA-
PKcs to directly bind DNA (Walker et al., 2001). DNA-PKcs can bind DNA in the absence of 
Ku subunits, but with greatly reduced affinity (Yaneva et al., 1997). These properties were 
first characterised when DNA-PK was identified to play a key role in double strand break 
repair within the nucleus (Lieber et al., 2003). In addition to this, there is evidence that DNA-
PK plays a role as a cytoplasmic DNA sensor. Firstly, the protein has been detected in the 
cytoplasm where it may function in the innate immune response (Huston et al., 2008). It has 
been shown that during VacV infection, DNA-PK co-localises at the sites of Vaccinia DNA 
replication. As well as this co-localisation, DNA-PK acts upstream of IRF-3 and TBK1 
leading to a type I interferon response (Ferguson et al., 2012). The subunit Ku70 has also 
been show to act as a cytosolic DNA sensor that induces a type III interferon response, 
rather than the well characterised type I response to intracellular DNA (Zhang et al., 2011a). 
Transfection of DNA, from various sources including viral, induces the activation of IFNL1 
and production of IFN λ mediated by the activation of both IRF1 and IRF7 (Zhang et al., 
2011a). This shows that DNA-PK as well as its subunit Ku70, can work together or 
individually to activate type 1 and 3 interferon responses in an IRF dependent manner. 
 
Meiotic Recombination 11 (Mre11) 
Meiotic Recombination 11, as with DNA-PK, is a previously well characterised DNA damage 
factor that has shown properties of a cytosolic DNA sensor (Kondo et al., 2013). Mre11 is 
commonly found within the MRN complex which also contains nijmegen breakage syndrome 
1 (NBS1) and a RAD50 homolog (Stracker and Petrini, 2011). Mre11, similar to DNA-PK, is 
widely recognised for its role DNA double strand break repair and genomic stability (Buis et 
al., 2008). However, Mre11 has been shown to be required for the DNA stimulated IFN 
response in dendritic cells from mouse bone marrow origin (Kondo et al., 2013). 
Components of the MRN complex such as Mre11 and RAD50 were shown to be crucial for 
DNA induced IFN response, whereas other components such as NBS1 had little or no effect 
on cytoplasmic DNA sensing (Kondo et al., 2013). Furthermore, Mre11 driven IFN response 
only occurred in response to transfected DNA and not with intracellular pathogens. Cells 
infected with either HSV-1 or Listeria monocytogenes did not exhibit an Mre11 depended 
IFN response (Kondo et al., 2013). Therefore the role of Mre11 depended DNA sensing 
during infection is debateable. 
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RNA polymerase III (Pol III) 
As stated previously, RIG-I and MDA5 have an important role in RNA sensing and IFN 
production, especially during viral infection. However, even though RIG-I is a cytosolic RNA 
receptor, studies have shown that it is capable of acting as an indirect DNA sensor (Chiu et 
al., 2009). RNA polymerase III is a specialised transcription protein important for the 
production of non-protein coding RNA transcripts, such as tRNAs, snRNAs, 5S rRNA as well 
as other essential RNA (Dieci et al., 2013). Alongside this, RNA polymerase III has been 
shown to transcribe synthetic poly(dA-dT) DNA when transfected into cells (Chiu et al., 
2009). Cytosolic B-form DNA such as poly(dA-dT) is converted into 5’ triphosphate double 
stranded RNA, which is then able to induce IFNβ production through the RIG-I pathway and 
culminating in the activation of IRF3 and NF-kB (Chiu et al., 2009, Valentine and Smith, 
2010). An example for the importance of RNA polymerase III activation of RIG-I is in 
Varicella zoster (VZV) infections. In adults with severe VZV central nervous system 
infections, mutations within the Pol III gene were identified in a quarter of patients (Carter-
Timofte et al., 2018). Cells possessing these mutations display reduced expression of 
antiviral cytokines in response to poly(dA-dT) as well as an increased viral replication rate. 
This shows that Pol III has an important role in certain viral infections (Carter-Timofte et al., 
2018). However, transfection with most other IFN stimulating DNA motifs such as 
oligonucleotides derived from VacV, or DNA isolates from other bacteria and viruses do not 
result in the production of stimulatory RNA and RIG-I activation (Unterholzner et al., 2010). 
Although some evidence shows Poll III to act as a DNA sensor, most is the result of 
synthetic DNA stimulation, whether Pol III is a true DNA sensor is still controversial. 
 
Extrachromosomal Histone H2B 
During the search for cytoplasmic DNA sensors many proteins were shown to have intrinsic 
DNA sensing properties alongside their normal function, one such protein is histone H2B. 
Histones are essential proteins involved in the structure and organisation of chromatin, as 
well as this histone modification is especially important in gene activation and silencing 
(Kobiyama et al., 2013). Alongside its normal function histone H2B has been shown to exist 
within the cytoplasm where it acts as a DNA sensor (Kobiyama et al., 2013). H2B is able to 
detect fragmented double stranded DNA produced from either viral infections or cellular 
damage. Once bound to DNA H2B then interacts with MAVS causing the induction of IFN 
signalling through CIAO (COOH-terminal importin 9-related adaptor organising histone H2B 
and IPS-1) and TBK1 (Kobiyama et al., 2010). This shows that histone have an important 
role in viral infections and DNA damage, this is summarised in Figure 6. 
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Non-specific nucleic acid receptors  
Several non-specific nucleic acid sensors have been identified that are able to recognise 
both DNA and RNA. These sensors enable an innate immune response towards nucleic 
acids in general, as opposed to targeted receptors. It has also been suggested that more 
general nucleic acid sensing is required for activation of more specific PRRs such as TLRs 
and intracellular DNA sensors (Yanai et al., 2009) 
 
High mobility group box 1 (HMGB1) is a non-histone chromosomal protein that functions as 
a DNA chaperone within the nucleus (Goodwin et al., 1977). In eukaryotic cells, HMGB1 is 
found within the nucleus and in the cytoplasm where it has many functions. HMGB1 is 
mostly found in the nucleus where its main role is to associate with DNA and aid with 
replication, repair, and stabilisation of the genome (Lee et al., 2014). Within the cytoplasm, 
its main role is to maintain homeostasis by regulating autophagy and reduce protein 
aggregation caused by cellular stress (Lee et al., 2014). As well as this cytoplasmic HMGB1 
can also act as a proinflammatory cytokine when released from cells, particularly activated 
macrophages (Yanai et al., 2009). Furthermore, HMGB1 also shows properties of a DNA 
Figure 6: DNA sensing by the histone H2B in damaged and virally infected cells. 
Under normal cellular conditions the histone H2B is localised in the nucleus where it is important for 
chromatin organisation and structure. During cellular damage or viral infection, DNA fragments in 
the nucleus are recognised by H2B. After binding DNA H2B forms a complex with CIAO and 
MAVS, also known as ISP-1, which induces TBK1 activation and subsequent IRF3 
phosphorylation. Phosphorylated IRF3 then translocates to the nucleus where it activates type 1 
interferon genes (Kobiyama et al., 2013).   
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sensor. Within the cytoplasm HMGB1 is able to bind DNA or RNA with high affinity, once 
bound it promotes the activation of TLRs and cytoplasmic DNA sensors (Yanai et al., 2009) 
 
Another non-specific nucleic acid sensor is Leucine-rich repeat flightless-interacting protein 1 
(LRRFIP1). As with other non-specific nucleic acid sensors LRRFIP1 is able to bind both 
DNA and RNA with high affinity. However, activation of LRRFIP1 stimulates IFN producing 
genes without activating IRF3. Instead, it is able to signal through the co-activator pathway 
containing β-catenin and p300 which can modify histones to enhance transcription of IFN 




Figure 7: The activation of type I IFN by cytoplasmic DNA and RNA sensing 
There are many intracellular DNA sensors, each with a distinct mechanism of action. Most of the 
DNA sensors converge on the common signalling pathway through STING and IRF3, with the 
exception of RNA pol III and LRRFIP1. RNA pol III is an RNA polymerase that is able to convert 
viral DNA into RNA that is then sensed by RIG-I and MAVS and leads to IRF3 dependent IFN 
production. LRRFIP1 is a non-conventional sensor as, instead of signalling via STING, it is able to 
activate β-catenin and modify histones to enhance IFN transcription. Regardless of activation 
method, all intracellular DNA sensor result in the activation of transcription factors NF-κB or IRF3 
and IFN gene transcription (Unterholzner, 2013). 
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1.6 Vaccinia Immune evasion 
The innate immune system possesses a wide array of mechanisms and factors that limit and 
destroy invading pathogens. Despite this poxviruses, including Vaccinia, are able to 
effectively infect and replicate within a human host. This is due to their large repertoire of 
innate immune evasion strategies (Smith et al., 2013). As it is the most studied member of 
the family, most Poxviridae innate immune evasion strategies were discovered in VacV. The 
collective research into VacV immune evasion has shown that it is able to inhibit or 
counteract almost all parts of the innate immune response, particularly disrupting the actions 





























Table 1: Proteins produced by VacV and their function on the innate immune 
system. 
VacV is able to produce a wide range of proteins that disrupt the immune system and allow 
replication. These proteins, produced mostly in early infection, effect all parts of the innate immune 
system including complement system, NK cells, TLR and RLRs, and IFN signalling. Shown in the 
table is the majority of the known VacV proteins, their function on the innate immune system and 
mechanism of action. Each protein is also discussed in detail in the text.  
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1.6.1 Complement 
The complement system is an important early host defence system, able to destroy viruses 
and virally infected cells before significant replication can occur. The main process behind 
this is virion opsonisation by antibodies and promoting destruction by phagocytosis 
(Dunkelberger and Song, 2010). To counteract this VacV produces and secretes the protein 
Vaccinia virus complement control protein (VCP). VCP is a 35kDa protein that is structurally 
similar to the potent complement inhibitor C4b binding protein (Jha and Kotwal, 2003). VCP 
is able to directly bind to both C3b and C4b and, with the aid of factor I, promotes cleavage 
of both proteins. The result of this is the blockage of both the classical and alternate 
complement pathways. This is an important extracellular immune control protein as VacV 
strains lacking the gene encoding VCP, C21L, are attenuated in vivo (McKenzie et al., 1992) 
 
1.6.2 Cell mediated innate immunity 
Cell mediated innate immunity plays an important role in viral infection by preventing further 
spread of the pathogen as well as activating the adaptive immune response. One of the 
main innate cellular components that play an important role in VacV infection are NK cells 
(Caligiuri, 2008). VacV is able to modulate NK cell activation by interfering with IL-18 
dependent activation of NK cells (Born et al., 2000) as well as directly infecting NK cells at 
the site of infection (Kirwan et al., 2006). Furthermore, The VacV protein A56 is abundantly 
present on a cell surface when infected with VacV, which is a ligand for the NK cell receptors 
NKp30 and NKp46 (Jarahian et al., 2011). These interactions block NKp30 triggered 
activation of NK cells and stimulate NKp46 depended activation. This results in a subset of 
activated NK cells with reduced cellular activity and a decreased susceptibility of infected 
cells to NK mediated lysis (Jarahian et al., 2011) 
 
1.6.3 Nucleic Acid Sensors 
One of the simplest ways VacV is able to avoid innate immune system is to prevent viral 
PAMP recognition by PRRs. Most PRRs are able to sense viral nucleic acids, therefore 
VacV has developed mechanisms to prevent this. VacV genes located at the terminal 
regions of the genome can only be transcribed outwards, towards the terminus, and from 
only one DNA strand (Smith et al., 1998). This limits the formation of immunostimulatory 
dsRNA. As well as this, early replication of VacV genome occurs in ER-enclosed 
cytoplasmic “viral factories”. These may isolate the VacV genome from any cytoplasmic DNA 
sensor (Tolonen et al., 2001). 
 
Toll-like receptors have an important role in innate defence against viruses as they are able 
to recognise viral DNA and stimulate IFN production. TLR signalling is dependent of the 
 34  
 
interactions of the TIR domains of the receptor with specialised adaptor molecules, 
specifically MyD88 and TRIF (Botos et al., 2011). Vaccinia virus is able to exploit this 
common signalling pathway with the protein A46. The viral protein A46 is a Vaccinia 
produced TIR domain containing protein that specifically counteracts multiple TLR signalling 
pathways (Stack et al., 2005). These interactions interfere with the downstream activation of 
both NF-κB and IRF3 hindering the host cytokine and interferon response. Alongside A46 
production, VacV also produces the protein A52 that stimulates cytokine production 
(Maloney et al., 2005). The VacV protein A52 interacts with tumour necrosis factor receptor-
associated factor 6 (TRAF6) resulting in the polyubiquitination of TRAF6 and induction p38 
MAP kinase pathway. This results in the production of the immunoregulatory cytokine IL-10 
(Maloney et al., 2005). As well as this, A52 is also able to block the activation of NF-κB and 
therefore limit cytokine production (Harte et al., 2003).  
 
As well as TLR inhibition VacV also produces proteins that inhibit or prevent RLR activation 
by dsRNA. VacV has an AT rich genome, making it particularly prone to sensing via Pol III 
(Valentine and Smith, 2010). However, VacV is able to limit this with the protein E3, a 
bifunctional Vaccinia protein with both DNA and RNA binding domains (Marq et al., 2009). 
By binding dsRNA, E3 is able to prevent the interaction of viral RNA with PRRs, thus limiting 
an intracellular immune response. As well as this, E3 has been shown to bind to 
immunostimulatory RNA produced by Pol III activation and prevent activation of the RIG-I 
pathway (Valentine and Smith, 2010). 
 
Other nucleic acid sensors alongside TLR are targeted by VacV for immune evasion. The 
protein E3 contains both a C-terminal RNA and N-terminal DNA binding domain and 
therefore prevents either from triggering PRRs (Marq et al., 2009). The N-terminal DNA 
binding domain shares homology with the DNA sensor DAI. This allows E3 to sequester any 
free viral DNA and prevent any potential interaction with cytoplasmic DNA sensors (Marq et 
al., 2009). Furthermore, E3 is able to competitively bind VacV DNA and prevent DAI 
activation and the resultant necroptosis (Koehler et al., 2017).  VacV is also able to limit 
sensing of nucleic acids by other DNA sensors. The viral protein C16 is able to bind to the 
Ku70 subunit of DNA-PK blocking DNA interaction and preventing the activation of IRF3, 
therefore blocking IRF-dependent IFN signalling (Peters et al., 2013)  
 
1.6.4 The cGAS-STING pathway 
The cGAS-STING pathway is one of the most important sensing pathways for VacV 
detection, due to its entirely cytoplasmic replication cycle. Because of this VacV utilises a 
number of mechanisms to disrupt the normal function of this pathway, although many 
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proteins involved are currently unknown. One of the mechanisms of inhibition utilised by 
VacV is to interfere with the normal function of the key adaptor protein STING. During 
infection VacV is able to prevent STING activation by blocking its phosphorylation and 
therefore dimerisation (Georgana et al., 2018). This inhibition of STING dimerisation by 
VacV prevents IRF3 activation even when cells are stimulated with DNA or cGAMP, 
although cGAMP degradation may also occur (Georgana et al., 2018). During normal cellular 
function, PKB is able to phosphorylate cGAS and supress its activity (Seo et al., 2015). This 
mechanism could potentially be exploited by VacV. Within Vaccinia infected cells PKB is 
activated, this is due to the virus utilising the pathway for its own replication (Soares et al., 
2009). Furthermore, PKB activation also leads to a reduction in cellular cGAMP and IFN-β 
production. This could be due to activated PKB phosphorylating and supressing cGAS 
activity, although this has yet to be directly observed with VacV infections (Seo et al., 2015). 
As well as inhibiton of key proteins in the cGAS-STING pathway, VacV has been shown to 
promote degradation of key proteins (Meade et al., 2018). The VacV core protein F17 is able 
to sequester key regulators of mammalian target of rapamycin complexes (mTORC); 
Regulatory-Associated Protein of mTOR (RAPTOR) and Rapamycin-Insensitive Companion 
of mTOR (RICTOR) (Meade et al., 2018). By removing regulatory proteins VacV infection 
results in the dysregulation of mTOR pathway, resulting in cGAS localisation in the golgi and 
driving its proteasomal degradation (Meade et al., 2018). Interestingly, this was observed 
fully in dermal fibroblasts but only partial cGAS degradation occurred in the human 
monocyte cells THP-1, suggesting F17 only targets a sub population of cGAS (Meade et al., 
2018). Furthermore, F17 is a late VacV protein so the aformentioned mechanism may only 
occur after replication of the viral genome. 
  
1.6.5 Interferons 
The interferon response is the most important antiviral innate immune response as it 
activates cellular components of both the innate and adaptive immune systems, stimulates 
nearby cells to produce antiviral proteins, and facilitate apoptosis of infected cells. Due to 
their many functions interferons are an integral part of the hosts antiviral response, because 
of this VacV has developed a wide range of proteins to counteract IFNs. VacV is able to 
interfere with every step of IFN signalling (Smith et al., 2013). 
 
One of the simplest ways VacV is able to prevent IFN production is to inhibit host protein 
synthesis. This is achieved by the viral decapping enzymes D9 and D10 (Parrish et al., 
2007). These proteins are able to bind to mRNAs and remove their 5’ methylated cap, 
resulting in their degradation. As well as this, D9 and D10 also target and degrades Vaccinia 
mRNA, preventing accumulation in the cytoplasm, and limiting an antiviral response by RNA 
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sensors, such as RIG-I (Liu et al., 2015). As well as preventing PAMP recognition by PRRs, 
VacV is also able to block parts of the signalling pathway leading to NF-κB or IRF3 activation 
and subsequent IFN production. 
 
VacV produces many proteins during early infection that are able to inhibit both IRF3 and 
NF-κB activation . Although all these are expressed at the same time during early infection, 
each protein is able to inhibt different stages of each signalling pathway. Many of these 
proteins share homology as they all contain the conserved B-cell lynphoma-2 (Bcl-2) fold 
(Kvansakul et al., 2017).   
 
Inhibition of IRF3 activation 
In addition to NF-κB Vaccinia also targets IRF3 in its immune evasion stratergies (Figure 8). 
IRF3 depended IFN signalling is initiated by several receptors such as TLRs, RLRs and 
intracellular DNA sensors; however, all these receptors share a common signalling pathway 
that converges on TBK1. Therefore unsurprisingly, VacV targets this in an attempt to disrupt 
IRF3 signalling. Firstly, the viral protein C6 prevents IRF3 activation by interacting with 
several key TBK1 complex scaffold proteins; TRAF family member-associated NF-κB 
activator (TANK), NAK-associated protein 1 (NAP1), and similar to NAP1 TBK1 adaptor 
(SINTBAD) (Unterholzner et al., 2011). These interactions inhibit the downstream activation 
of TBK1 and IRFs without effecting NF-κB (Unterholzner et al., 2011). Another protein able 
to interact with TBK1 scaffold proteins is K7. During early infection K7 is able to bind to 
DDX3, an important for the TBK1-mediated activation of IRF3 and ifnb promoter induction 
(Schröder et al., 2008). This results in the inhibition of IRF activation via TBK1/IKKε. As well 
as this, the viral prtoteins SPI-2 and CrmA are also able to inhibit activation of IRF3 (Qin et 
al., 2017). Both viral proteins are able to associate with TBK1 and IKKε and disrupt the 
phosphorylation, therefore activation, of STING and IRF3. As with C6, SPI-2 and CrmA 
disrupt IRF3 activation without effecting NF-κB activation (Qin et al., 2017). A more unusual 
example of IRF3 signalling disruption is by the viral protein N2. Unlike most VacV proteins, 
N2 is localised within the host cells nucleus were it is able to inhibit the transcriptional activity 
of IRF3 (Ferguson et al., 2013).  
 















Figure 8: Inhibition of the IRF3 signalling pathway by VacV 
Pathway activation occurs when viral nucleic acids interact with PRRs in the cytoplasm or endosome. 
There are two main activation pathways, either via TRAF3 or STING, both converging on a common 
signalling pathway via TBK1 and IRF3. Once IRF3 is phosphorylated it forms a dimer where it 
translocates to the nucleus and acts as a transcription factor. VacV proteins are able to disrupt this at 
multiple points, these are shown in the figure and discussed further in the text (Smith et al., 2013).  
 
Inhibition of NF-κB activation  
Activation of NF-κB is an important step in viral innate immunty as it leads to the production 
IFNs and many proinflammatory cytokines, able to limit viral replication. Therefoe VacV 
produces multiple proteins that limit its activation (Figure 9). Many VacV proteins are able to 
directly bind to NF-κB signalling pathway components and disrupt their function, such as the 
viral protein K1. When expressed K1 is able to prevent the acetylation of the NF-κB subunit 
p65 preventing its activation (Bravo Cruz and Shisler, 2016). Other VacV Bcl-2 proteins 
disrupt NF-κB signalling further downstream, by interrupting the normal function of inhibitor 
of κB kinase (IKK). The VacV proteins N1 and B14 have both been shown inhibit NF-κB 
activation by drisupting IKK. B14 is able to bind the the IKK subunit IKKβ, preventing its 
phosphorylation and therefore preventing the phophorylation of the inhibitor of κB (IκBα) 
(Chen et al., 2008). By preventing the phosphrylation of IκBα, NF-κB remains bound to IκB 
and therfore inactive. Similarly, N1 is also able to bind to the IKK complex and disrupt NF-κB 
activation (DiPerna et al., 2004). Alongside direct interactions with IKK, VacV produces the 
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protein A49 which mimics a stable phophorylated IκBα (Mansur et al., 2013). Under normal 
signalling conditions, IκBα is phosporylated by IKKβ and then ubiquinated by the E3 ligase 
β-TrCP resulting in IκBα degradation and NF-κB activation, A49 is able to bind β-TrCP 
preventing this (Mansur et al., 2013).  
Figure 9: Inhibition of the NF-κB signalling pathway by VacV 
The pathway leading to NF-κB can be activated by both the intracellular and extracellular binding of 
nucleic acids to PRRs. Also shown is the activation by IL-1 binding to its receptor. Once PRRs bind to 
nucleic acids signalling occurs that activates TRAF6, resulting the phosphorylation and activation of 
IKK. Active IKK is able to dissociate IκB from NF-κB by targeting for proteosomal degradation. The 
action of VacV preventing this are shown as discussed further in the text (Smith et al., 2013). 
 
Disruption of IFN signalling 
As well as preventing IFN production, VacV is also able to prevent the dissemination and 
downstream signalling of IFNs. After IFNs are produced and released from cells, VacV is 
able to prevent IFNs from reaching their receptors by producing a number of soluble 
extracellular proteins including B18; a type I IFN binding protein(Xu et al., 2008) and B8; a 
soluble IFN receptor (Alcamí and Smith, 1996). Signal transduction from IFN signalling is 
also prevent in infected cells, due to the STAT phosphatase VH1 (Koksal et al., 2009).  
Despite VacV producing a wide array of proteins enabling multi-step inhibition of IFN 
signalling, most are required for effective replication. Mutations or loss of one or several of 
the immune evasion proteins result in reduced virulence and potentially ineffective 
replication (Smith et al., 2013). Suggesting that these immune evasion strategies do not 
display redundancy.  
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1.7 Aims 
In this project, the ability of VacV to inhibit DNA sensing by the innate immune system, 
during early infection, is being investigated. The aim of this project are: 
 To determine if VacV can inhibit the normal function of intracellular DNA sensors, 
with a focus on cGAS. 
 To determine mechanisms and proteins involved in the inhibition of DNA sensing by 
VacV 
This will be achieved by using molecular techniques such as western blotting, qPCR and 
cloning to detect cGAS changes during VacV infection and identify proteins involved. By 
achieving these aims, we hope to uncover a mechanism employed by VacV, during 
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2 Materials and Methods 
2.1 Cell culture 
Immortalised human keratinocytes (HaCaTs) were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Life Technologies) with the addition of 10% (v/v) Fetal Calf Serum (FCS) 
(Sigma) and 50μg/ml Gentamicin (Life Technologies). HEK293T cells (Thermo, HCL2517) 
were grown in DMEM with the addition 10% (v/v) Foetal Calf Serum (FCS) (Sigma) and 
50μg/ml Gentamicin (Life Technologies). All cells were grown at 37°C with 5% C02 
For viral work; BS-C-1, BHK21, and RK13 cells were used. These cells were grown in 
DMEM with the addition 10% (v/v) Foetal Calf Serum (FCS) (Sigma) and 50μg/ml 
Gentamicin (Life Technologies).  
 
2.2 Buffers Used 
10X Tris Buffered Saline (TBS) pH 7.6 
0.2M Tris base 
1.5M NaCl 
H20 
Mammalian Cell Lysis Buffer 
50mM Tris-HCl (pH 7.5)  
1mM EDTA  
1mM EGTA  
1% (v/v) Triton X-100  
1mM Sodium Orthovanadate 
 50mM Sodium Fluoride 
 5mM Sodium pyrophosphate  
10mM Sodium β-glycerophosphate 
 0.27M sucrose  
0.1% (v/v) β-mercaptoethanol 
 0.1mM PMSF  
10μl/ml Aprotinin 
3x SDS Sample Buffer 
62.5mM Tris-HCl (pH 6.8)  
2% (w/v) SDS  
10% (v/v) Glycerol  
0.1% (w/v) Bromophenol blue  
H2O 
50X TAE 
2M Tris Base  
5.7% (v/v) Glacial acetic acid  
50mM EDTA (pH 8)  
H2O 
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Resolving Gel Buffer (pH 8.8) 
1.5M Tris Base 
H20 
Stacking Gel Buffer (pH 6.8) 
0.5M Tris Base 
H20 
6x DNA Loading Buffer 
30% (v/v) Glycerol 
 0.025% (w/v) Bromophenol blue  
0.025% (w/v) Xylene cyanol 
 H2O 
Table 2: Buffers used throughout this project. 
 
2.3 DNA transfection 
DNA transfections in HaCaT cells were performed using Lipofectamine 2000 (Invitrogen) to 
the manufacturer’s instructions, by using 1µg DNA: 1µl of Lipofectamine 2000 per 
transfection. Treatment of cells with Lipofectamine 2000 alone was used as a control. DNA 
transfection in HEK293T cells were performed using GeneJuice (Novagen) to the 
manufacturer’s instructions, by using 1µg DNA: 3µl GeneJuice. For double stranded DNA 




All inhibitors were dissolved in dimethyl sulfoxide (DMSO; Agilent) and applied to cells 1 
hour before stimulation or infection. DMSO was used as a control for all inhibitors. The 
proteasome inhibitor MG132 (Sigma) was used at 10μM. The autophagy inhibitor 
Bafilomycin A1 (Sigma Aldrich) was used at 500nM. The general caspase inhibitor Q-VD-
Oph (R&D systems) was used at 10µM.  
 
2.5 Immunoblotting 
Proteins were separated by size using sodium-dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE).  
1.5mm 12% polyacrylamide gels were produced using the following: 











4.4ml 3.0ml 2.5ml 0.1ml 0.05ml 0.005ml 
A higher percentage gel was used to seal the plates before addition of the resolving gel to 
prevent leaking. The plug was produced as follows: 
250µl Resolving gel mix (without APS or TEMED) 
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5.0µl 10% APS 
0.5µl TEMED 











1.9ml 0.3ml 0.75ml 0.03ml 0.03ml 0.003ml 
Table 3: Production of 12% polyacrylamide gels. 
 
Cultured cells were lysed in Mammalian cell lysis buffer on ice for 30 minutes. Lysate was 
scraped into clean Eppendorfs (Eppendorf) and centrifuged at 12,000 rpm on a benchtop 
centrifuge for 10 minutes and supernatant moved to a fresh tube. Samples were denatured 
using SDS sample buffer at 99°C for 10 minutes before loading onto SDS-PAGE gels 
 
SDS-PAGE gels were run in a Mini-Protean Tetra Cell tank (Biorad) at 120V for 1.5Hours or 
until the dye reached the bottom of the gel. SDS-PAGE gels were transferred onto a 
polyvinylidene difluoride (PVDF) membrane (Immobilon), which was activated in 100% 
methanol before use. The transfer occurred in a semi-wet transfer pack for 1 hour at 0.1Amp 
per SDS-PAGE gel. Membranes were blocked using either 5% BSA (Sigma)/TBS/0.1% 
Tween or 5%non-fat milk (Marvel)/TBS/0.1% Tween depending on antibody compatibility 
with the buffer. After blocking the membrane was incubated with antibodies (see antibody 
section) at dilution 1:1000 in either 5% BSA/TBS/0.1% Tween or 5%non-fat Milk 
(Marvel)/TBS/0.1% Tween at 4°C overnight. Blots were then washed 3 X 5 minutes in TBS-
0.1%Tween  then incubated with secondary antibody, either anti-Rabbit-IgG-HRP (Horse 
Radish Peroxidase) or anti-Mouse-IgG-HRP (Horse Radish Peroxidase) at dilution 1:3000, 
for 3 hours at room temperature. The blots were then developed with ECL (Bio-Rad) by UV 
exposure with Chemidoc (Bio-Rad) 
 
2.6 Co-Immunoprecipitation 
Cells were lysed in mammalian cell lysis buffer. After lysis cells were centrifuged at 1000g 
for 3 min to pellet cell debris. Samples were pre cleared using Protein G agarose beads 
(Thermo Scientific) for 1 hour at 4°C. Samples were then centrifuged at 1000 X g for 5 
minutes and supernatant collected. This supernatant was incubated with 1:2000 FLAG 
antibody overnight, followed by addition of fresh Protein G Spharose 4 Fast Flow beads (GE 
healthcare) for 3 hours at 4°C. After incubation, beads were washed 3 times with 
Mammalian cell lysis buffer, proteins bound to beads were eluted with 100ug/ml FLAG 
peptide/TBS (Sigma) for 1 hour. After Flag peptide elution, beads were washed 3 times with 
Mammalian cell lysis buffer, the resultant samples were analysed by Mass Spectrometry. 
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Small aliquots were taken from each step and mixed with 3X SDS sample buffer + DTT 
(150nM), then boiled at 99°C for Western blot analysis. These were used as an input control 
and for quality assurance. 
 
For analysis of samples by Mass Spectrometry, the sample was treated with Trichloroacetic 
acid (TCA) to precipitate proteins. TCA was added to sample in a 1:4 (TCA:Sample) ratio, 
vortexed and incubated at 4°C for 10 minutes. Samples were then centrifuged at 13000 x g 
for 5 minutes to pellet the precipitate. Pellet was washed with ice cold acetone and air dried. 
Once air dried, pellet was resuspended in PBS overnight at 4°C. Resuspended samples 
were then mixed with 4X NuPAGE LDS Sample Buffer (Life technologies), 10X NuPAGE 
Reducing Agent (Life technologies) and deionised H20. Samples were heated at 70°C for 10 
minutes then loaded onto a precast NuPAGE 4-12% Bis-Tris Mini Gel (Life technologies). 
The gel was run following manufacturer’s instructions by using MES buffer at 200V for 30 
minutes or until the dye reached the bottom of the gel. The resultant gel was sectioned into 
equal parts and analysis by peptide mass fingerprinting at the FingerPrint Proteomics Facility 
(University of Dundee) 
 
2.7 qRT-PCR 
RNA was extracted from cells using RTK lysis buffer and ethanol. Extracted RNA was 
filtered through High Filter tubes using RNA Isolation Kit (Roche Applied Science), including 
a DNase step using 10µl DNase to 90µl DNase incubation buffer (Roche). RNA 
concentration was measured by using a Nanodrop 2000c spectrophotometer (Thermo 
Scientific) and equal amounts of RNA were taken from each sample. 
 
cDNA was synthesised by reverse transcription of RNA by using iScript cDNA Synthesis Kit 
(Bio-Rad); using 0.5µl iScript reverse transcriptase and 2µl 5X iScript reaction mix, samples 
were made up to 10µl with nuclease-free H2O in 8-tube PCR strips (Brand). iScript samples 
were then run on Eppendorf Master Cycler for 5 minutes at 25°C, 30 minutes at 42°C, 5 
minutes at 85°C, then cooled to 4°C. 
 
qRT-PCR was performed using 2X Fast SYBR green mastermix (Roche; SYBR Green I dye, 
AmpliTaq Gold DNA Polymerase, dNTPs with dUTP Passive Reference, and optimised 
buffer components). The master mix also contained Taq polymerase which, with specific 
oligonucleotide probes, amplifies target genes by PCR (polymerase chain reaction). The 
mastermix also contains SYBR Green I; a dsDNA specific fluorescent dye, used to detect 
and quantify amplified PCR products. The qRT-PCR was performed on an Applied 
Biosystems StepPlus One Real-time PCR machine, with the following programme;  
Holding Stage (1 cycle): 1 minute at 90°C 
 44  
 
Cycling Stage (35 cycles): 15 seconds at 95°C, 1 minute at 60°C 
Melt Curve Stage (1 cycle): 15 seconds at 95°C, 1 minute at 60°C, 15 seconds at 95°C, 15 
seconds 60°C 
 
Primers were designed through NCBI Primer Blast and synthesised by MWG-Biotech. 
Primers were designed to be specific only for the gene of interest, and span multiple introns 
to avoid amplification of genomic DNA. The following primers were used at the final 
concentration of 500nM. 
Gene Forward Primer Reverse Primer 




IFNβ ACGCCGCATTGACCATCTAT GTCTCATTCCAGCCAGTGCT 
cGAS GGGATGGTGAAAGGGGTTGT GCAGAAATCTTCACGTGCTCA 
Table 4: Primers used in this project. 
 
2.8 Bacterial transformation and Maxiprep 
NovaBlue competent E.coli cells (Novagen) were incubated with DNA for 5 minutes on ice, 
then heat shocked at 42°C for 30 seconds before cooling on ice for a further 5 minutes. 
100µl of SOC (Super Optimal Broth with Catabolite repression) media (Novagen) was added 
to the mixtures and plated onto LB agar plates with added Ampicillin. Plates were produced 
from LB agar powder (Novagen; 5g yeast extract, 10g peptone, 10g NaCL, 12g agar) 
dissolved in 1L of distilled water and heated in a microwave until boiling for 2 minutes. Once 
cooled, Ampicillin (Formedium) was added at 150µg/ml. Plates were then incubated 
overnight at 37°C. Single colonies were then picked and incubated in 3ml of Ampicillin 
containing LB broth on a shaking incubator for 6 hours. LB broth was made from LB Broth 
powder (Novagen; 5g yeast extract, 10g peptone, 10g NaCL) dissolved in 1L of distilled 
water and heated by microwave until boiling. After cooling Ampicillin (Formedium) was 
added at 150µg/ml. After incubation, the bacterial suspension was moved into 100ml of 
Ampicillin LB broth and incubated in a shaking incubator at 37°C overnight. The bacterial 
suspension was centrifuged at 15,000 x g for 10 minutes in the Avanti J-26 XP centrifuge 
using the J-Lite Series Rotor JLA-16.250 (Beckman Coulter). Bacterial pellets were lysed 
and plasmids were purified using the Maxiprep kit (Qiagen).  
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2.9 Plasmids used 
pcDNA3.1(+) EV was purchased from Clontech. pcDNA3.1(+):cGAS-FLAG was generated 
by J. Almine (University of Lancaster). 
 
2.10 Agarose Gel Electrophoresis  
1% Agarose gels were produced using Ultrapure Agarose (Invitrogen) dissolved in 1xTris-
Acetate-EDTA (Ethylenediaminetetraacetic acid) buffer (TAE; 2M Tris Base, 5.7% (v/v) 
glacial acetic acid. 50mM EDTA (pH 8), then heated in a microwave until boiling. After 
cooling, 1X SYBR safe stain was added and gently mixed. Agarose was then poured into a 
gel tray with well combs in place (VWR) and allowed to set at room temperature. Once set, 
the gels were placed in a gel tank and submerged in 1XTAE. 
 
DNA samples were mixed with 3x DNA loading buffer. To provide size markers, a 2-log DNA 
ladder (Peqlab) was also mixed with DNA loading buffer. Both the samples and the DNA 
ladder were then loaded onto the gel, which was run at 5-7V/cm using a power pack (VWR) 
for 1.5 hours or until the dye had moved over half-way down the gel. Gels were then imaged 
on a GelDoc EZ Imager (Bio-Rad) using Image Lab Software (Bio-Rad) 
 
2.11 Antibodies Used 
Target Species Company Catalogue number 
Β-actin Mouse Sigma Aldrich A2228 
IFI16 Mouse Santa Cruz 8023 
cGAS Rabbit Cell Signaling  15102 
STING Rabbit Cell Signaling 13647 
IκBα Mouse Cell Signaling 4814 
FLAG-tag Mouse Sigma F3165 
Anti-mouse-HRP Goat Cell Signaling 4414 
Anti-rabbit-HRP Goat Cell Signaling 8889 
Table 5: Antibodies used in this project.  
 
2.12 Subcloning of cGAS  
cGAS gene sequences was obtained using NCBI Gene database and restriction sites were 
checked using NED Cutter to identify 0 cut restriction enzymes. The restriction enzymes 
selected were Xhol (for forward primer and Not1 for reverse primer. By using the high fidelity 
polymerase, Herculase II, amplification of the cGAS insert by PCR occurred. This was 
performed using the following programme: 
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Holding Stage (1 cycle): 2 minute at 95°C 
Amplification Stage (35 cycles): 20 seconds at 95°C, 20 seconds at 52°C, 1 minute at 72°C 








Table 6: Primers used for subcloning of Cgas 
 
2.13 Virus work 
All viruses were stored at -80°C, defrosted thoroughly and mixed before use.  
The viruses used throughout this project were: VacV-A5-EGFP, a VacV with GFP bound A5 
protein and MVA 
 
2.13.1 Virus propagation and purification 
Flasks of either RK13 (VacV) or BHK21 (MVA), in DMEM + 10% FBS and gentamicin 
50µg/ml, were infected with their respective viruses for 3 days (VacV) or 5 days (MVA). Cells 
were then scraped into media and collected in Falcon tubes (Falcon). The suspension was 
then centrifuged at 2000rpm in a benchtop centrifuge, the pellet washed, then re-centrifuged 
at 2000rpm for 10 minutes. The resultant pellet was then resuspended in 10mM Tris-HCL 
(pH9) and incubated on ice for 15 minutes. After incubation the cells were Dounce 
homogenised with 25 strokes before centrifugation at 1000rpm for 5 minutes. The 
supernatant was then layered above a 36% (w/v) sucrose/10mM Tris-HCL (pH9) solution in 
a polycarbonate ultracentrifuge tube. Further 10mM Tris-HCL (pH9) was added to the tube 
to ensure over half full and balanced. The tubes were then centrifuged in the Avanti J-26 XP 
centrifuge at 16500rpm for 70 minutes at 4°C using the JA-25.50 Fixed-Angle Rotor 
(Beckman Coulter). The supernatant was aspirated and the pellet resuspended in 10mM tris-
HCL and stored at -80C before a plaque assay was performed to determine PFU. 
 
2.13.2 Plaque assay  
BS-C-1 cells were seeded in 6 well plates and grown in DMEM + 10% FCS until a confluent 
monolayer was achieved. A serial dilution of the virus into serum free DMEM was performed 
to obtain dilutions from 10-2 to 10-8, which was then added to each well. The virus was 
allowed to infect the cells for 1 hour, with gentile rocking every 15 minutes. After incubation 
the virus was removed and the cells were covered with 1:1 ratio of 3% Carboxymethyl 
cellulose and 2X DMEM (Milipore; with additional 100nM sodium pyruvate, 7.5% (w/v) 
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sodium bicarbonate). Cells were then incubated until visible plaque could be seen; 3 days 
(VacV), 5 days (MVA). The cell overlay was then removed and wells were washed 3 times 
with sterile PBS, before staining with Crystal violet + Methanol. Cells were stained for 30 
minutes before removing the stain, then plates were air dried at room temperature. Once 
dry, visible plaques were counted and multiplied by the dilution factor to obtain plaque 
forming units per ml (PFU/ml). 
 
2.13.3 Viral Infection 
VacV and MVA were added at specified Multiplicity of Infection (MOI) to cells, in serum free 
DMEM, for one hour at 37C with 5% CO2. During this hour the plate was rocked gently every 
15 minutes. After one hour infection the media along with the virus was removed, the plate 
was washed with PBS then fresh DMEM + 10% FBS was added. The plate was then 
incubated for 4 hours, after which the cells were lysed on ice with mammalian cell lysis 
buffer. 
 
2.14 Statistics  
Results from RT-PCR analysis are presented as averages of biological triplicate samples 
with standard deviations displayed as Error bars. Statistical testing was performed using 
GraphPad QuickCalcs software. Statistical significance was determined using unpaired two 
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3 Results 
3.1 Cytosolic DNA activates the cGAS-STING pathway leading to IFNβ 
production 
Cytoplasmic DNA is known to be recognised by the cGAS-STING pathway and promote IFN 
production (Sun et al., 2013). Transfection of HT DNA into wild type keratinocytes cells 
(HaCaT) was performed to show this. Cells transfected with DNA showed activation of 
STING (Figure 10.A), seen by the change in the ratio of phosphorylated (higher band) and 
non-phosphorylated STING (lower band). The total STING levels in the cells also reduced 
significantly, most likely due to the degradation of STING after activation (Konno et al., 
2013). This shows that DNA promotes STING activation in HaCaT cells. To determine the 
effect STING activation has on IFNβ production, HaCaT cells were stimulated with DNA for 6 
hours and mRNA levels were measured by RT-PCR using IFNβ specific primers. After DNA 
stimulation a clear 140 fold induction of IFNβ could be seen in the HaCaT cells (Figure 
10.B). These result show that when HaCaT cells are stimulated with DNA STING is 
activated and IFNβ production is induced, suggesting cytoplasmic DNA sensor activation. 
These results were used as the baseline data for IFN induction with DNA when comparing to 
DNA virus infection. 














3.2 Growth and purification of MVA stocks 
Before infections could occur a stock of MVA with a known concentration would need to be 
generated. First MVA was grown in baby hamster kidney cells (BHK21) for 5 days, after 
which the cells were lysed by Dounce homogenisation and virus purified using sucrose 
cushion centrifugation. To determine the concentration of the virus sample obtained a plaque 
assay was performed (Figure 11). Monolayers of BS-C-1 cells were infected with MVA at 
dilutions 10-5 to 10-10 and allowed to infect cells for 1 hour in serum free DMEM. Virus was 
then removed and a semi-solid overlay media, complete DMEM + 3% carboxymethyl 
cellulose (CMC), was added to cells to inhibit viral dissemination and cell-to-cell 
transmission. After 5 days cells were stained and fixed with a crystal violet methanol 
solution. The visible plaques of dead cells were then counted (Figure 11). This gave the titre 
of MVA (4x108 pfu/ml) which was then used in subsequent infections.  
Figure 10: DNA stimulation promotes IFNβ production and STING activation 
in wild type HaCaT cells.  
A. WT HaCaT cells were either stimulated with 5µg/ml Lipofectamine 2000 (Lipo) or DNA, as 
indicated, for 4 hours in complete DMEM after which cells were lysed in mammalian cell 
lysis buffer. Cell lysates were separated by SDS-PAGE and analysed by immunoblotting 
with indicated antibodies.   
B. WT HaCaT cells were stimulated with 5µg/ml Lipofectamine 2000 or DNA for 6 hours, as 
indicated. Cells were then lysed in RNA lysis buffer and analysed by RT-PCR. The results 
shown are averages of three biological triplicates. Error bars displayed represent standard 
deviation. A two-tailed unpaired T-test was performed and is displayed as *** (<0.001). 
 










3.3 VacV infection limits IFNβ mRNA upregulation when compared to DNA 
stimulation.  
To determine if DNA viruses could induce the same levels of IFNβ mRNA as direct DNA 
transfection, VacV and the attenuated DNA virus MAV were used. MVA is an attenuated 
cytoplasmic DNA poxvirus closely related to VacV. MVA was produced by multiple passages 
through chicken fibroblasts, resulting in a 10% loss of genetic material compared to VacV. 
MVA lacks several key immune evasion genes found in VacV which contributes to its 
attenuated phenotype (Antoine et al., 1998). This results in MVA being unable to limit the 
cellular IFN response during infection.  
 
As DNA transfection stimulates IFNβ upregulation, the DNA viruses VacV and MVA were 
investigated to determine if they were able to induce IFNβ. HaCaT cells were infected with 
MVA or VacV using a multiplicity of infection of 1 (MOI 1), for 1 hour in serum free DMEM. 
After this, media was removed and replaced with DMEM + 10% FBS and incubated for 6 
hours. This was performed alongside a 6 hour stimulation of HaCaT cells with HT DNA. After 
incubation, cells were lysed and mRNA levels were measured by RT-PCR using IFNβ 
specific primers. When HaCaT cells were stimulated with HT DNA, there was a 160 fold 
increase of IFNβ compared to the mock. MVA infection also resulted in elevated IFNβ levels, 
around 40 fold increase, but did not induce IFNβ by the amounts seen in DNA transfection 
Figure 11: Modified Vaccinia Ankara plaque assay. 
A monolayer of BS-C-1 cells were infected with MVA at the dilutions shown, allowed to infect cells, 
and then immobilised with CMC. After 5 days cells were stained and fixed with a crystal 
violet/methanol mixture. After staining, areas of dead cells (plaques) were counted, the result was 
multiplied by the dilution factor to determine plaque forming units (pfu). Red arrows indicate visible 
plaques. 
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(Figure 12). A two tailed T-test showed that the increase in IFNβ observed in MVA was not 
statistically significant (P= 0.149, due to a large standard deviation). VacV infection has a 
minor effect on IFNβ production, as infection only lead to a 20 fold increase. This suggest 




















3.4 Both MVA and VacV have minimal effect on CCL5 mRNA upregulation 
compared to DNA transfection. 
When cells are infected with viruses many proinflammatory cytokines are produced in an 
attempt to combat the infection. To determine the effect of MVA and VacV infection on 
cytokine production, CCL5, a chemokine upregulated during DNA stimulation (Levy, 2009), 
was investigated. HaCaT cells were infected with MVA or VacV (MOI 1), for 1 hour in serum 
free DMEM. After that, the media was removed and replaced with DMEM + 10% FBS and 
incubated for 6 hours. This was performed alongside a 6 hour stimulation of HaCaT cells 
with HT DNA. After incubation cells were lysed and mRNA levels were measured by RT-
PCR using CCL5 specific primers. HT DNA stimulated cells show a 90 fold increase in CCL5 
mRNA compared to the lipofectamine control (Figure 13). However, both MVA and VacV did 
not show a significant increase of CCL5 mRNA. This shows that DNA transfection stimulates 
Figure 12: VacV infection limits IFNβ mRNA upregulation in HaCaT cells. 
WT HaCaTs were either stimulated with 5µg/ml DNA or infected with MVA or VAcV (MOI 1) for 6 
hours, as indicated. Cells were then lysed in RNA lysis buffer and analysed by RT-PCR. The results 
shown are averages of three biological triplicates. Error bars displayed represent standard 
deviation. A two-tailed unpaired T-test was performed and is displayed as *** (<0.001). The T-test 
showed that MVA was not statistically significant compared to mock infection (P= 0.149, due to a 
large standard deviation. 
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CCL5 production, but the DNA viruses MVA and VacV did not result in significant CCL5 



















3.5 Vaccinia targets the cGAS-STING pathway to prevent IFN production  
Transfection of HaCaT cells with DNA results in a significant upregulation of IFNβ and CCL5 
however, this upregulation was limited in VacV infections. Suggesting VacV possesses 
mechanisms to limit cytokine production. VacV has been shown to produce multiple proteins 
that interfere with the innate immune response. The cGAS-STING pathway has been shown 
to be the main pathway that detects VacV in infected cells, and activation of this pathway 
leads to IFNβ production (Sun et al., 2013). To investigate the ability of VacV to limit IFNβ 
production during HaCaT infection, the cGAS-STING pathway was observed during 
infection. HaCaT cells were transfected for 4 hours with HT DNA, this was then compared to 
HaCaT cells infected with either MVA or VacV. Cells were inoculated with either MVA or 
VacV (MOI 1) for 1 hour in serum free DMEM, after which was replaced with DMEM +10% 
FBS. The cells were then incubated for 4 hours, after which cells were lysed by mammalian 
cell lysis buffer and analysed by Western blotting. Both DNA and MVA resulted in the 
activation of STING, shown by the presence two STING bands and a reduced levels of 
STING Figure 14.A. This is because, when STING is activated it becomes phosphorylated, 
the higher band visible in Figure 14.A, and after phosphorylation it is targeted for 
Figure 13: MVA and VacV infections cause reduced CCL5 production in HaCaT 
cells, when compared to DNA transfection. 
Wild type HaCaTs were either stimulated with 5µg/ml DNA or infected with MVA or VacV (MOI 1) 
for 6 hours, as indicated. Cells were then lysed in RNA lysis buffer and analysed by RT-PCR using 
CCL5 specific primers. The results shown are averages of three biological triplicates. Error bars 
displayed represent standard deviation. A two-tailed unpaired T-test was performed and is 
displayed as *** (<0.001). 
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degradation by autophagy (Konno et al., 2013). During DNA and MVA infection cGAS 
remains largely unaffected, though a slight reduction during MVA infection is observed. 
During VacV infection STING activation is prevented and cGAS levels are reduced and 
become undetectable. These observations show that VacV is able to interfere with cGAS to 
prevent STING activation and therefore limit IFNβ production. 
 
In human keratinocytes, cGAS and IFI16 cooperate to activate STING during DNA sensing 
(Almine et al., 2017). IFI16 levels were investigated in HaCaT cells infected with VacV, to 
determine if IFI16 is lost during infection. Cells were infected with MVA and VacV (MOI 1), or 
stimulated with DNA. While VacV infection induces the loss of cGAS, IFI16 levels remain 

















3.6 Vaccinia targets cGAS directly for degradation during infection 
Infection of HaCaT cells with VacV results in the loss of cGAS. To determine how VacV 
causes this, cGAS expression at the mRNA level was investigated. Previously VacV has 
been shown to directly affect host cell mRNA levels during infection (Parrish et al., 2007). To 
determine if VacV supresses the expression of cGAS mRNA, cellular mRNA levels were 
investigated in uninfected, DNA stimulated, and MVA or VacV infected HaCaT cells. Cells 
were treated with DNA or infected with MVA or VacV (MOI 1) for 6 hours. This time point 
was selected as cGAS is undetectable by Western blot from 4h, therefore any effect on 
mRNA should be clear by 6 hours. HaCaT stimulation with DNA and infection with both MVA 
B 
Figure 14: VacV infection results in the loss of cGAS, but not IFI16, preventing 
STING activation. 
A. Effect of DNA, MVA and VacV on cGAS levels and STING activation 
B. Effect of DNA, MVA and VacV on cGAS and IFI16 levels 
For both figures, WT HaCaT cells were either transfected with 5μg/ml HT DNA for 4 hours, or 
infected with MVA or VacV (MOI 1), as indicated. Cells were infected for 1h in serum free DMEM, 
after which the media was replaced with DMEM + 10% FBS and incubated for 4h. Cells were lysed 
in mammalian cell lysis buffer and cell lysates were separated by SDS-PAGE. Gels were then 
analysed by immunoblotting with indicated antibodies. 
 
A 
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and VacV infection caused a minor (around 1.5-fold) increase in cGAS mRNA levels (Figure 
15), although the increase was shown to be insignificant by T-test. This shows that DNA 
stimulation and DNA viruses have little or no effect on the expression levels of cGAS mRNA, 





















To determine if VacV is able to directly target the cGAS protein for degradation, HEK293T 
cells were transfected with a plasmid containing the FLAG tagged protein cGAS-FLAG. 
These are an ideal cell type to study VacV/cGAS interactions as HEK293T cells lack many 
proteins in the DNA sensing pathway, including cGAS. Cells were transfected with a range 
of cGAS-FLAG concentrations to determine which levels mimic normal cellular levels. After 
allowing plasmid expression overnight, cells were infected with VacV (MOI 1) for 1 hour in 
serum free DMEM, after which they were incubated for 4 hours in DMEM + 10%FBS. These 
conditions are the same for HaCaT infections to allow direct comparison. Figure 16 shows 
that levels of cGAS-FLAG higher than 0.5 µg/ml saturate the virus during infection and no 
significant cGAS loss can be seen. When lower concentrations of cGAS-FLAG are used 
(less than 0.5 µg/ml) results similar to HaCaT infection can be seen, as cGAS is lost after 4 
hours. This suggests that during infection VacV is able to directly target and reduce cGAS 
Figure 15: cGAS mRNA remains stable during DNA stimulation and viral infection. 
WT HaCaT cells were stimulated with either 5μg/ml DNA or Lipofectamine 2000 and infected with 
with either VacV or MVA, both MOI 1. Cells were treated for 6 hours then were lysed in RNA lysis 
buffer. Lysates were analyses by RT-PCR in triplicate, then normalised to mock infection. The 
results shown are averages of three biological triplicates. Error bars displayed represent standard 
deviation. A two-tailed unpaired T-test was performed and found the increase of MVA and VacV 
from mock to be not statistically significant, P= 0.117 and P=0.062 respectively. 
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3.7 Vaccinia does not use cellular degradation pathways to induce cGAS loss 
To determine how VacV reduces cGAS levels during infection, cellular degradation 
pathways were investigated. The three main pathways in cells that lead to protein 
degradation are the proteasome, autophagy and caspases. These pathways were targeted 
for inhibition to investigate if VacV is drive cGAS loss by use of host degradation pathways 
 
Autophagy is a lysosome dependent form of protein degradation within cells and is important 
in protein recycling. Targeted components are isolated and packaged in a cytoplasmic 
double membrane vesicles, autophagosomes. These autophagosomes then bind with 
lysosomes and target proteins are enzymatically degraded. This process is inhibited using 
the Streptomyces griseus derived Bafilomycin A1 by preventing V-ATPase dependent 
acidification of the autophagosome (Mauvezin and Neufeld, 2015). A control test was 
performed to determine efficacy before usage. DNA stimulation leads to STING activation 
and subsequent degradation, this degradation event uses the autophagy pathway (Konno et 
al., 2013). HaCaT cells were stimulated with DNA for 2 and 4 hours, with and without pre-
treatment with Bafilomycin A1. Figure 17.A shows that DNA activates STING and after 
activation it is degraded, shown by the reduced band at 4h. Cells pre-treated with 
Bafilomycin A1 for 1h then stimulated with DNA still show STING activation, but no 
degradation occurs. This shows that Bafilomycin A1 treatment effectively inhibits autophagy 
in HaCaT cells.   
 
Figure 16: Transfected cGAS-FLAG is also targeted by VacV. 
HEK293T cells were transfected with a cGAS-FLAG containing plasmid, and allowed to express 
the protein overnight. A subset of these transfected cells were infected with VacV (MOI 1) for 4 
hours. All cells were then lyses in mammalian cell lysis buffer, separated by SDS-PAGE then 
analysed by immunoblotting with an anti-FLAG antibody.  
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Another degradation pathway targeted for inhibition was the proteasome. Proteins are 
targeted for degradation by the addition of ubiquitin molecules, ubiquitination, catalysed by 
ubiquitin ligases. Tagged proteins are then targeted by the proteasome for proteolytic 
cleavage (Tanaka, 2009). This process can be inhibited by carbobenzoxy-Leu-Leu-leucinal 
(MG132), as it blocks all proteolytic activity of the proteasome complex (Lee and Goldberg, 
1998). To test this inhibitor HaCaT cells were stimulated with tumour necrosis factor (TNFα) 
for 15 minutes and IκBα degradation was investigated. TNFα stimulation leads to the 
activation of TNF receptor-associated factor 2 (TRAF2) and subsequent activation of IκB 
kinase, resulting in the degradation of IκBα (Wajant and Scheurich, 2001). Figure 17.B 
shows that when cells are stimulated with TNFα it results in the proteasomal degradation of 
IκBα. This should be prevented by MG132, but Figure 17.B shows MG132 has a minor 















After inhibitor efficacy was determined, the compounds were used alongside VacV infections 
to determine if host cellular degradation pathways were involved in the loss of cGAS. HaCaT 
cells were pre-treated with each inhibitor for 1 hour, after which they were inoculated with 
Figure 17: Bafilomycin A1 and MG132 are able to inhibit autophagy and the 
proteasome, respectively.  
A. WT HaCaT cells were pre-treated with 50nM Bafilomycin A1 for 1 hour, after which they 
were stimulated with DNA for either 2 or 4 hours.  
B. WT HaCaT cells were pre-treated with 10μM MG132 for 1 hour, after which they were 
stimulated with 10μg/ml TNFα for 15 minutes. 
All cells were lysed in mammalian cell lysis buffer, separated by SDS-PAGE and then analysed by 
immunoblotting with the indicated antibodies.    
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VacV for 1 hour. Virus was then removed and fresh media was added, cells were left to 
incubate for 4 hours. When each inhibitor was used, cGAS loss caused by VacV infection 
was not prevented (Figure 18). As well as the aforementioned inhibitors, MG132 and 
Bafilomycin A1, the caspase inhibitor Q-VD-Oph was also used. Caspases are cellular 
proteases well defined for their role in apoptosis, however they also function in cell 
homeostasis and autophagy (Shalini et al., 2015). A Q-VD-Oph control experiment was not 
performed due to time constraints, although this is explored further in the discussion section. 
When treated with MG132 and Bafilomycin, some cGAS is still present after VacV infection 
as a faint band can be seen Figure 18. This was determined not to be significant as the 
majority of cGAS was still lost after VacV infection. These results show that VacV does not 







3.8 Identifying VacV proteins that bind cGAS 
As VacV does not use host cellular degradation pathways to promote cGAS loss, it was 
determined that VacV must target cGAS directly. To identify any VacV proteins that were 
able to interact with cGAS an immunoprecipitation (IP) of the cGAS protein was performed. 
However, before performing VacV infections, it needed to be determined if cGAS could be 
isolated from cell lysates by IP. To test this, HEK293T cells were transfected with plasmids 
containing either cGAS-FLAG or IRF3-FLAG. IRF3-FLAG was used as a positive control for 
the IP due to previous experiments demonstrating its ability to be pulled down from lysate. 
Transfected cells were allowed to express proteins overnight, after which they were lysed 
and proteins were isolated from lysates by FLAG-IP. A FLAG elution was performed to elute 
proteins from the FLAG antibody and eluted proteins were analysed by Western blot. Figure 
19 shows that HEK293T cells are able to express the cGAS-FLAG containing plasmid which 
can then be isolated by FLAG IP. 
Figure 18: Inhibition of the proteasome, autophagy, or caspase activity does not 
prevent cGAS degradation by VacV. 
Wt HaCaT cells were pre-treated for 1 hour with the indicated inhibitors, after which cells were 
infected for 4 hours with VacV (MOI 1). Cells were then lysed in mammalian cell lysis buffer, 
separated by SDS-PAGE then analysed by immunoblotting with indicated antibodies. 
 











Once it was determined that cGAS-FLAG could be pulled down by IP, this was used to 
investigate if any VacV proteins bind to cGAS during infection. However this presented a 
problem, as cGAS is lost within 4 hours of VacV infection. To circumvent this restriction, 
lysates from 2 subsets of HEK293T cells were used and then mixed. Cells were either 
transfected with cGAS-FLAG and allowed to express the plasmid, or infected with VacV 
(MOI 1), after which cells were lysed and lysates mixed. This ensured that VacV would have 
sufficient time to express the proteins that facilitate cGAS loss and could be mixed with cell 
lysate containing cGAS-FLAG to observe interactions with cGAS. To maximise the amount 
of VacV proteins and cGAS, this experiment was done at a large scale. HEK293T cells were 
grown in 15cm diameter dishes with 9x106 cells per plate; 5 plates were transfected with 
empty pcDNA 3.1 vector, 5 plates were transfected with pcDNA 3.1 cGAS-FLAG, and 10 
plates were infected with VacV (MOI 1). All transfections were performed with 20µg/mL of 
DNA. Cells were lysed and lysates were mixed overnight at 4°C. After mixing cGAS, was 
isolated from the lysate by FLAG-IP and eluted by FLAG elution. The eluted proteins were 
then precipitated using trichloroethanoic acid/methanol precipitation, then dissolved in PBS. 
Samples were separated on a 4-12% Bis-Tris gel and stained with Coomassie for 1 hour, 
then cut into equal parts (Figure 20). The samples were then sent to be analysed by peptide 
mass fingerprinting at the FingerPrint Proteomics Facility (Dundee). After analysis, VacV 
proteins were identified using the Universal Protein Resource database (Pundir et al., 2017). 
Viral proteins unique to the cGAS-FLAG containing samples are shown in Table 7. Proteins 
Figure 19: cGAS-FLAG can be isolated from HEK293T cell lysate by IP. 
HEK293T cells were transfected with plasmids containing cGAS-FLAG and IRF3-FLAG, and 
allowed to express these proteins overnight. After which, cells were lysed and the indicated 
proteins were isolated from the lysates using FLAG IP and FLAG elution. Whole cell lysate (WCL) 
was used as an IP control. Samples obtained from IP were separated by SDS-PAGE and 
analysed using FLAG antibody. Whole cell lysis is shown as an input control and was processed 
under the same conditions.  
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identified were mostly VacV structural or replication proteins and many were found within the 




















Figure 20: Coomassie stained Bis-Tris gel of FLAG IP from HEK293T cell lysates 
HEK293T cells were seeded into 20, 15cm diameter plates, at 9x106 cells per plate; 5 were 
transfected with pcDNA 3.1 EV, 5 were transfected with pcDNA cGAS-FLAG, and 10 were infected 
with VacV (MOI 1) for 4 hours. Cells were then lysed and each transfection lysate was mixed with 
an equal amount of VacV infected cell lysate, at 4°C overnight. After mixing, cGAS was isolated 
from the lysate by FLAG-IP and eluted by FLAG elution. The eluted proteins were then precipitated 
using trichloroethanoic acid/methanol precipitation, then dissolved in PBS. Samples were 
separated on a 4-12% Bis-Tris gel, stained with Coomassie and cut into equal sections, as shown. 
Samples were then sent for analysis by peptide mass fingerprinting at the FingerPrint Proteomics 
Facility (University of Dundee) 
Table 7: VacV proteins identified by mass spectrometry after FLAG IP in cGAS-
FLAG containing HEK293T cells. 
Results generated from the peptide mass fingerprinting were compared against the Universal 
Protein Resource database (Pundir et al., 2017). Shown is the proteins only found in the cGAS-
FLAG cells and their function in viral infection.  
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3.9 Generation of pcDNA5/FRT/TO-GFP cGAS plasmid 
Once VacV that associate with cGAS are identified, they would be tested for their ability to 
induce cGAS loss seen during infection. Potential candidate VacV proteins and genes, 
identified from the co-IP, would be tested for their ability to induce cGAS loss. This would be 
performed in a HEK293T cell line that is stably transfected and expresses cGAS. Therefore, 
stable HEK293T cells expressing cGAS would need to be generated. The Flp-In system was 
selected as it allows integration of target plasmids into the host cell genome. Firstly, the 
cGAS coding sequence from the plasmid pcDNA 3.1 cGAS-FLAG needed to be amplified 
using cGAS primers to generate the insert that would be used in the Flp-In system. Before 
this, restriction enzymes needed to be selected to enable insert of the cGAS sequence 
without causing cleavage of either the vector or insert. The Vector selected was 
pcDNA5/FRT/TO-GFP which contains a FRT/TO site that when used with the Flp-In system 
results in genome integration, also GFP is present downstream of the multiple cloning site 
causing any insert genes to produce a protein tagged with GPF at the C-terminus. The 
restriction sites present within its multiple cloning site were tested against the cGAS insert 
using NEBcutter (Vincze et al., 2003). The restriction enzyme sites selected were Not1 and 
Xhol. These restriction enzymes were tested against the pcDNA5/FRT/TO-GFP vector to 
ensure they do not cleave aberrantly (Figure 21.A). After it was determined that the 
restriction enzymes only cut at the desired places, they were tested against the cGAS insert 
(Figure 21.B). This showed that the selected enzymes, Not1 and Xhol, only cut the vector 
and insert at the desired position. Both the vector and insert were digested by the restriction 
enzymes and allowed to ligate. After ligation the plasmid was propagated in E.coli and single 
colonies were selected and plasmids were purified by Miniprep. The resultant plasmids 
underwent a restriction digest with Not1 and Xhol, to determine if ligation was successful.  
Figure 21.C shows that all samples, except one, contained the correct insert. Samples in 
lanes 3 and 4 were taken and purified by Maxiprep.  



















Figure 21: Subcloning of the plasmid pcDNA3.1 cGAS-FLAG to produce the 
plasmid pcDNA5/FRT/TO-GFP cGAS-FLAG. 
A. The restriction enzymes Not1 and Xhol were selected. The vector pcDNA5/FRT/TO-GFP 
was digested with Not1 and Xhol, a double digest was also performed.  Lanes represent; 
1= ladder, 2=Uncut vector, 3=Not1 cut vector, 4=Xhol cut vector, 5=Not1 and Xhol cut 
vector 
B. To determine if Not1 or Xhol aberrantly cut the pcDNA5/FRT/TO-GFP vector or the cGAS 
insert a single digest was performed on both. Lanes represent; 1=Ladder, 2= Uncut vector, 
3= Uncut insert, 4=Not1 cut vector, 5=Xhol cut vector, 6=blank lane, 7=Not1 cut insert, 
8=Xhol cut insert. 
C. After vector and insert were ligated they were expressed in E.coli and grown on selectivity 
media. Single colonies were then taken and expanded in media broth. These were then 
purified by Miniprep and the resultant plasmids were checked for the correct insert. Lanes 
represent; 1=Ladder, 2= Xhol and Not1 cut vector, 3= Xhol and Not1 cut insert, 4-8= Single 
colony Minipreps. 
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4 Discussion 
Smallpox was once a devastating human disease, but was eventually eradicated by use of 
the poxvirus VacV. Long after smallpox eradication, VacV is still an area of great interest 
regarding the understanding of the innate immune system, as it successfully evades many 
antiviral processes; specifically DNA sensing and IFN production. Interactions between VacV 
and the innate immune system is an intensely studied area, which has discovered many 
VacV immune evasion strategies as well as widening our understanding of the innate 
immune system. One such study was the identification of the cytosolic DNA sensor cGAS 
and its essential role in DNA virus sensing (Sun et al., 2013). Since the discovery of the 
cGAS-STING pathway it has been of great interest in understanding VacV immune evasion. 
To date cGAS is known to be the primary DNA sensor of VacV, and the virion counters this 
by effecting downstream proteins such as STING and IRF3 (Georgana et al., 2018), as well 
as interacting with DNA sensors directly (Peters et al., 2013, Meade et al., 2018). Despite 
this, many questions still remain about the mechanism VacV employs to disrupt DNA 
sensing.   
 
The aim of this study was to investigate the immune evasion mechanisms VacV possesses 
in order to counter DNA sensing in host cells. For this study it was determined that HaCaT 
cell lines were the most representative cell type for multiple reasons. Firstly, keratinocytes 
are one of the main sites of poxvirus infection, therefore HaCaT cell lines provided the most 
biologically relevant cell types (Boukamp et al., 1988). In addition to this, HaCaT cells have 
been shown to possess multiple DNA sensors which cooperate in IFN production upon DNA 
stimulation (Almine et al., 2017). Initial infection of HaCaT cells with VacV showed a 
reduction in cGAS levels by 4 hours post infection. This reduction resulted in cGAS being 
undetectable by Western blot, suggesting VacV is able to induce total loss of cGAS within 4 
hours of infection. This provided the main focus area of this study. 
 
During infection with VacV, the loss of cGAS prevented the activation of STING resulting in 
reduced IFN production. The downstream proteins IRF3 and TBK1 were not investigated 
during this study, though cGAS loss and lack of STING activation would likely result in no 
activation of IRF3 and TBK1. This could be determined by investigating the whole cGAS-
STING pathway during DNA stimulation, MVA, and VacV infection. By infecting HaCaT cells 
and lysing at specific time points before cGAS is lost, the whole cGAS-STING pathway can 
be investigated during the first hours of infection. This can be performed by Western blot 
using antibodies specific for pathway proteins e.g. IRF3, TBK1, cGAS and STING. 
Surprisingly VacV did not target other DNA sensors for degradation that cooperate with 
cGAS to activate STING. The AIM2-like DNA sensor IFI16 has been shown to work 
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alongside cGAS to activate STING, especially in keratinocytes (Almine et al., 2017). This 
study shows that, even though VacV promotes the degradation of cGAS, IFI16 remains 
intact and is not targeted for degradation. Degradation of IFI16 could still occur but at a later 
timescale not used in this study. Conversely, VacV may produce a protein that, while it does 
not degrade IFI16, could potentially block interaction between IFI16 and cGAS to limit 
STING activation, a mechanism seen in other VacV proteins (Chen et al., 2008, Mansur et 
al., 2013, Peters et al., 2013). Further study would be needed to determine if VacV is able to 
directly target IFI16 during infection. This could be performed using confocal microscopy, by 
investigating VacV interactions with key DNA sensors during infection. Cells would be 
infected with VacV at specific time points and imaged using fluorescently labelled antibodies, 
able to target viral proteins expressed in early and late infection, as well as host proteins. 
The advantage of this would be the ability to track VacV localisation with DNA sensors at 
specific time points during infection. If both cGAS and the virus localise at specific locations, 
this could provide an insight into how VacV is able to promote loss of cGAS.  
 
Inhibition of transcription would result in a reduction in cGAS mRNA and reduced protein 
levels. This mechanism could be employed by VacV during infection to reduce levels of 
cGAS. Therefore, the ability of VacV to influence cGAS transcription was investigated. At 6 
hours post infection cGAS mRNA levels remained unchanged, suggesting VacV does not 
affect cGAS at the mRNA level. This lead to the hypothesis that VacV is able to facilitate the 
degradation of cGAS by manipulating the host protein degradation pathways. Testing with 
autophagy, caspase and proteasome inhibitors did not prevent cGAS degradation, showing 
VacV does not use host cell degradation pathways to induce cGAS loss. However, by 
blocking one degradation pathway VacV may be able to utilise an alternative degradation 
pathway to induce the loss of cGAS. To determine this, cells would be treated with all three 
aforementioned inhibitors and the effect on cGAS degradation by VacV would be observed. 
Although care would need to be taken as inhibition of multiple essential cell pathways can 
lead to premature cell death.  
 
Blockage of host cell degradation pathways did not prevent the loss of cGAS during VacV 
infection, suggesting VacV is able to produce an enzyme that specifically targets cGAS for 
degradation. This has been observed in many other VacV proteins that target innate immune 
proteins for degradation (McKenzie et al., 1992, Jha and Kotwal, 2003). However, while 
enzymatic cleavage is likely, no degradation or cleavage products are seen on any of the 
cGAS blots. This could be because cGAS cleavage by VacV coincidentally disrupts the 
antibody binding site. This would result in immunoblotting yielding no results, even if 
degradation products were present. To identify these products, cGAS tagged with FLAG at 
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both the N and C terminus could be used. By transfecting cells with cGAS containing a 
FLAG tag at both the N and C terminus, anti-FLAG antibodies can be used to detect 
degradation products. This was explored superficially in this study with the plasmid 
pcDNA3.1 cGAS-FLAG, but no degradation product was seen.  
 
Before using each inhibitor, a positive control was designed to ensure that the target 
pathway was sufficiently inhibited. However, as mentioned briefly in the results section, no 
positive control has been performed with Q-VD-Oph. This was because, unlike Bafilomycin 
and MG132, no experiment could be designed which used simple techniques such as 
immunoblotting. Despite this, a positive control was designed, although never performed due 
to time constraints. To test the ability of Q-VD-Oph to inhibit caspase activity, cells would be 
treated with etoposide, which is able to associate with genomic DNA of cells causing double 
strand breaks and inducing apoptosis. The number of apoptotic cells can be measured by 
flow cytometry and annexin A5 staining, a dye commonly used to detect apoptotic cells. This 
can be then used to measure the ability of pre-treatment with Q-VD-Oph to limit apoptosis. 
 
A recent study has identified the VacV protein F17 that is able to target cGAS for 
degradation during infection (Meade et al., 2018). While this result supports the observations 
reported in this study, several key points differ. Firstly, F17 is a late VacV protein, that is only 
expressed when mature intracellular virion formation begins, around 6 hours post infection 
(Wickramasekera and Traktman, 2010, Wittek et al., 1984). This is shown by inhibition of 
viral transcription, and therefore late mRNA formation, by cytosine arabinoside resulting in 
no F17 production (Wittek et al., 1984). Furthermore, due to the nature of the process 
described; dysregulation of the mTOR pathway by (Meade et al., 2018),  it was hypothesised 
that this is only relevant in late stage immune evasion, evident by the 24-40 hour time points 
used. In this study VacV was able to facilitate the complete degradation of cGAS within 4 
hours, suggesting an alternative early immune evasion mechanism. These conflicting results 
suggest that several mechanisms may be present to facilitate the degradation of cGAS, one 
important in early infection the other used in late infection. Meade et al., (2018), also showed 
that the proteasome is essential for F17 function as MG132 prevented the mTOR dependent 
cGAS loss. This contradicts the results shown in this study, as treatment with MG132 did not 
affect VacV ability to degrade cGAS. This further supports the hypothesis that several cGAS 
degradation pathways exist that occur at different stages of infection. To test this hypothesis 
several experiments can be performed. Firstly, cGAS is undetectable by Western blot 4h 
post infection with VacV, therefore immunoblotting of the F17 protein can be performed 4 
hours post infection to determine if VacV expresses this protein at this time point. If F17 is 
found to be expressed at 4 hours, co-IP can be performed to determine if RICTOR and 
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RAPTOR are sequestered. Furthermore, the described pathway results in mTOR 
dysregulation by VacV induced phosphorylation of mTORC1 substrates p70S6K and 4E-
BP1 and mTORC2 substrate PKB, phosphorylated at S473 (Meade et al., 2018). These can 
also be identified by Western blotting at the time VacV induced cGAS loss occurs in HaCaT 
cells, 4h post infection. 
 
To investigate interaction between viral proteins and cGAS a co-IP was performed. This 
initially presented a problem as cGAS is lost within 4h of VacV infection. This restricted 
cGAS pulldowns to very early infections, before many VacV proteins are expressed. To 
counteract this problem, two separate lysates were used. HEK293T cells were either 
transfected with cGAS-FLAG containing plasmids or infected with VacV, lysed then mixed. 
This enabled interactions between VacV proteins and cGAS, without the loss of cGAS. This 
allowed cGAS to be isolated by FLAG co-IP allowing investigation of VacV proteins bound to 
cGAS. Elution with FLAG peptide was performed after the IP to allow cGAS to separate from 
the bound antibody, ensuring the sample did not contain IgG heavy or light chains. IgG 
heavy and light chain are approximately 50kDa and 25sDa, respectively, around the size of 
both cGAS and VacV proteins (Janeway, 2005). Therefore, FLAG elution prevented any 
interference these may cause, especially when Immunoblotting.  
 
The results gained from peptide mass fingerprinting show that optimisation is needed before 
useful data can be generated. These results showed that HEK293T cells were successfully 
transfected with cGAS-FLAG and isolated from lysates by immunoprecipitation. However, 
this result was not confirmed by Western blotting, due to small sample volume and a 
concentrated sample resulting in overloading of the gel. This resulted in unusable Western 
blots and little sample available to rerun. This could be avoided by reconstituting the TCA 
precipitated sample in a higher volume and diluting the sample before loading onto a SDS-
PAGE gel. Many vaccinia proteins were identified by mass spectrometry, most of which are 
structural or important in viral replication, and many were also present in the empty vector 
control, where no VacV proteins should be isolated. This shows that the protocol is non-
specific and proteins bound to cGAS are not being discriminated from general viral proteins. 
A way in which specificity for proteins could be increase is to introduce more stringent 
washing steps during the IP to remove unbound viral proteins. The expression of the cGAS-
FLAG plasmid was also low when transfected into HEK293T cells. This is evident by no 
clear cGAS band visible in the Coomassie stained gels and low levels detected by mass 
spectrometry. This can be addressed by using higher amounts of plasmid DNA during 
transfection, allowing longer for the plasmid to be expressed or using a plasmid with stronger 
promoter.  
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During this study, the plasmid pcDNA5/FRT/TO-GFP cGAS-FLAG was produced, but was 
not used for its entire intended use due to time constraints. The overall objective was to 
create a stable GFP tagged cGAS containing HEK293T cell line by using the Flp-In system, 
which can then be used in viral infections. The Flp-In system allows integration and 
expression of genes into mammalian cells at targeted genomic locations. By introducing a 
FLP Recombination Target (FRT) site into the cell line genome, an expression vector 
containing the C-terminal GFP tagged cGAS can be integrated into the genome of HEK293T 
cells. This occurs via the Flp recombinase-mediated DNA recombination at the FRT site 
(O'Gorman et al., 1991). The cloned plasmid would contain GFP downstream of the multiple 
cloning site resulting in the expression of a protein tagged with GPF at the C-terminus. This 
would enable screening and identification to be performed via fluorescence and allowing 
study of VacV interaction with cGAS in isolation, due to Hek293T cells naturally lacking 
cGAS. After the generation of the cell line, data obtained from the co-IP identifying candidate 
VacV genes that target cGAS would be taken and tested against this cell line. Multiple VacV 
open reading frames of interest would be subsequently tested to identify candidate genes 
that promote the loss of cGAS. Once identified, knockout VacV could be generated to test 
these genes. If the identified gene was responsible for cGAS degradation, this degradation 
would be prevented with the KO virus. This gene sequence can also be compared against 
the MVA genome. MVA is a cytoplasmic DNA poxvirus closely related to VacV which, due to 
multiple passages through chicken fibroblasts, has lost around 10% of its genetic material. 
Therefore, MVA does not possesses all genes VacV has, and is attenuated in vivo (Antoine 
et al., 1998). However, during several infections with MVA, cGAS levels are reduced slightly 
compared to mock infection or DNA stimulation. This suggests that MVA may still possess 
functional genes able to target cGAS, similar to what is seen with VacV infections. However, 
MVA infections still resulted in STING activation suggesting DNA sensing was not affected 
by MVA to prevent pathway activation. While STING activation was observed, no significant 
IFNβ mRNA upregulation was seen with MVA infections. This could be due to not enough 
time between MVA infection and cell lysis to allow significant IFNβ upregulation.  
 
Identification of VacV proteins able to induce cGAS loss and disrupt DNA sensing provides 
potential clinical applications.  The cGAS-STING pathway is abnormally active in several 
diseases such as Lupus Erythematosus and Aicardi-Goutieres Syndrome, and often 
contributes to the disease phenotype (Gray et al., 2015, Wang et al., 2018a). Consequently 
the, Identification of cGAS inhibitors, derived from VacV, could lead to potential new 
treatments for such diseases. 
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5 Conclusion 
Intracellular DNA sensing through the cGAS-STING pathway is one of the most important 
viral sensing pathways in the innate immune system. Activation of this pathway leads to 
IFNβ production and subsequent virus clearance. During infection the cytoplasmic DNA virus 
VacV is able to facilitate the degradation of the key DNA sensor cGAS. With the loss of this 
DNA sensor, activation of key downstream signalling proteins such as STING is prevented 
and IFNβ production is blocked. The viral protein responsible for this is expressed in early 
infection, within 4 hours, and appears to target cGAS directly for enzymatic cleavage, 
although a candidate protein remains elusive. This provides valuable information regarding 
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